MUNDELEIN, IL–(Marketwire – September 13, 2010) –  Clinicians at Arkansas Methodist Medical Center (AMMC) are changing the way they assess and perform urinary catheter insertions — and it’s working. With the help of Medline Industries, Inc.’s ERASE CAUTI Foley catheter management system, which combines evidence-based principles and training with a revolutionary one-layer tray design, AMMC has seen a 21 percent reduction in catheterizations and catheter-associated urinary tract infections (CAUTI). Urinary tract infections (UTIs) account for 40% of all healthcare-associated infections according to the CDC. Urinary catheters are associated with the vast majority of those healthcare-acquired UTIs.⁽¹⁾

“The one-layer tray design is labeled in a specific sequence that helps guide our nurses during the catheterization process to adhere to current CDC recommendations, including aseptic technique,” said Lisa Bridges, RN, Infection Preventionist for AMMC. “To help us reduce catheterizations, we are requiring our entire nursing staff to take the program education on the alternatives to catheterization. Plus, the new tray has a checklist to help the nurse make a decision on whether catheterization is appropriate for the patient and assure that the education transfers into everyday clinical practice.”

As measured by the number of catheterizations performed in March and April 2009 versus the same time in period in 2010, AMMC reduced the number of catheterizations from 192 to 151, a 21 percent drop (based on adjusted patient day). This decrease contributed to the hospital achieving zero CAUTIs in April 2010, compared to three in April 2009, according to Bridges. 

Another leading factor causing CAUTI is leaving a catheter in place for more than two days after surgery.⁽²⁾  The new Surgical Care Improvement Project (SCIP) recommends removal of catheters within 24-48 hours post-operatively. In the first quarter of 2009, only 20 percent of the catheters AMMC placed in the O.R. were being removed within two days. With the implementation of the ERASE CAUTI program, the removal rate increased to 50 percent in the first quarter of 2010.

“With the Foley InserTag and checklist sticker placed on the patient’s chart, nurses and physicians knew exactly when the catheters had been placed,” said Bridges, “and were able to remove them in the necessary 24-48 hours after surgery.”

Also, inserted in the tray is a patient education care card that looks like an actual get well card. According to Bridges, the card is a more effective way to educate patients about the procedure, including the risks and complications associated with closed system Foley catheters.

“Before, we had to print our education from the computer, and it was not something the patient or the clinician normally took time to review,” said Bridges. “The patient care card has significantly improved our ability to provide patients and families with a tool to help them better understand the proper care and maintenance of the catheter, signs and symptoms of CAUTI and how they can help reduce the chances of developing CAUTI.” 

AMMC, a 129-bed inpatient facility located in Paragould, Arkansas, has more than 200 nurses on staff. Almost 25,000 patients visit the hospital’s emergency room annually; a total of 4,196 patients are admitted; and physicians perform 795 inpatient and 1,827 outpatient surgeries. 

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, IL, Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities, and on-staff clinicians.

⁽¹⁾ Catheter-related UTIs: a disconnect in preventive strategies. Physician’s Weekly. 2008; 24(6).

⁽²⁾ Wald HL, Ma A, Bratzler DW, Kramer AM. Indwelling urinary catheter use in the postoperative period: analysis of the national surgical infection prevent project data. Arch Surg. 2008; 143:551-557.

WINSTON-SALEM, NC–(Marketwire – September 13, 2010) –  Antimicrobial Technologies Group (ATG) announces they had a successful series of meetings in Winston-Salem as they reviewed several potential sites for establishment of their textile manufacturing and finishing needs. ATG has developed products that provide infection protection and odor control at the highest level of safety, efficacy and cost effectiveness for anti-bacterial, anti-viral, anti-fungal and anti-odor fabrics, fibers, plastics and paints.

Mark Fulk of Meridian Realty Group and Stan Cruitt of Grande Peak Technologies hosted Simon and members of his management team for their visit to the area.

According to Johnston the Winston-Salem and surrounding area has potential to satisfy ATG’s needs. “Mark and his team presented many attractive facilities to us for review and we do see a good fit,” says Johnston. “Although initially we may need a 100,000 square foot facility, our products are of such a scale that within a few years we could grow out of that space. We are very interested in creative thinking with regard to the RJR Whitaker plant.”

According to Stan Cruitt of Grande Peak Technologies, a specialty healthcare marketing company, the market potential for ATG’s products is significant and the capacity to utilize a plant the size of the Whitaker facility is not just a dream. “There are five very large textile related markets where ATG products can make a difference and gain substantial market share. The first is the hospitality and home linen market for sheets and pillow cases. Hotels and motels that provide odor free, bacteria free linens, which may also be prophylactic against bedbugs, will generate considerable demand and market presence. The second is the hospital specialty market which includes masks, scrubs, towels and linens,” Cruitt continues. “With more than 6,000 hospitals and 35 million patient discharges annually, the potential for high market share is driven by cost savings that hospitals can achieve. The third is the diabetic market for foot ulcer prevention. Nearly 23 million people in the US have diabetes and ATG’s socks for diabetics can help prevent the infections that often lead to slow healing wounds, and even amputations. No other product is available in US healthcare that provides continued control of the bacteria and fungi that lead to these problems. The fourth major market is the military for the supply of antimicrobial and antifungal socks and underwear. And lastly, the fifth is the sportswear market for sport bras, sport socks and more. Odor control, antibacterial, and antifungal are features that consumers will pay for.”

“We are enthusiastic about the possibilities and are looking forward to pulling together the necessary partners for creative planning,” says Fulk. “The opportunity that ATG brings could make Winston-Salem a primary incubator for specialty and medical textile manufacturing in the US and a major contributor for new jobs in our city. We believe ATG has the technology to back up the vision Simon Johnston has for his company.”

Johnston adds, “All of our products have the potential for international distribution which could lead to substantial exports from our North Carolina facility. Our technology is lower cost than other antimicrobials and longer lasting due to the re-chargeability feature. We prefer to manage all finishing and dying in the US but we’re also looking into the possibility of including the cutting, weaving, sewing in the facility for some of our more specialized products.”

About Antimicrobial Technologies Group: ATG has developed a number of patent pending and proprietary technologies that provide low cost, long-acting antimicrobial, antifungal and antiviral protections to a wide range of products including textiles for healthcare, sportswear, consumer, hospitality and other markets. Contact ATG at 425-891-9151.

About Grande Peak Technologies: Grande Peak is a healthcare marketing specialty company focused on launching new technologies into health markets. Contact Grande Peak at 336-414-9035.

About Meridian Realty Group: Meridian is a full-service commercial and industrial brokerage and management company based in Winston-Salem. Contact Meridian at 336-722-1986.

MONTVALE, NJ–(Marketwire – September 13, 2010) –  SRS, the leading provider of productivity-enhancing technology and services for high-performance physician specialty practices, today announced a partnership with Medstrat, the pioneer of orthopaedic PACS (digital x-ray) software. SRS will offer its clients an exceptional and innovative PACS system that is fully integrated with the SRS Hybrid EMR and the SRS CareTracker PM.

Capitalizing on its OpenPath™ technology, SRS will incorporate the PACS system so that clients access images directly from within the EMR. The product will be branded as the SRS PACS, powered by Medstrat, and will be implemented, supported, and serviced by SRS.

“PACS is another component of the SRS Unified Desktop that is essential for speed and productivity, and is particularly critical for orthopaedic surgeons,” says SRSsoft CEO Evan Steele. “We researched many PACS companies and selected Medstrat based on its dedication to orthopaedics and our shared commitment to customer service as the highest priority.”

“We are delighted to be working with the leading provider of EMR solutions for the orthopaedics community,” says Michael Cowden, Founder and CEO, Medstrat. “We look forward to jointly helping physicians provide the highest quality care and service to their patients in the most efficient manner.”

Michael Goebel, M.D., physician at Blue Ridge Bone & Joint Clinic in Asheville, NC, has been a successful user of both the SRS Hybrid EMR and Medstrat’s PACS system. “We are delighted that our two primary software vendors have formed this agreement to integrate their systems. Having a single product interface and support network through SRS is a big plus for us.”

About SRS

SRS is the recognized leader in productivity-enhancing EMR technology and services for high-performance orthopaedic practices — with the largest national network of orthopaedists successfully using an EMR. Its key products, the robust SRS Hybrid EMR and SRS CareTracker PM, offer powerful and flexible solutions that streamline clinical workflows and enhance patient care. SRS increases speed, frees physicians’ time, boosts revenue, and heightens patient satisfaction. Prominent orthopaedic groups overwhelmingly choose SRS because of its unique fit with the demands of their specialty. For more information on SRS, visit www.srssoft.com, e-mail [email protected], fax 201.802.1301, or call 800.288.8369.

About Medstrat
Medstrat originated digital x-ray imaging for orthopedic practices to meet the unique needs of the orthopedic surgeon and address the demanding challenges orthopedic surgeons face every day, including the pressure to reduce costs and deliver faster, higher-quality patient care. Based upon a proven, high-performing digital medical imaging platform, Medstrat allows for the elimination of film, chemicals, and processing, increases workflow efficiency and staff productivity, and provides significant cost savings. For more information, call 800-882-4224 or visit www.medstrat.com.

IRVING, TX–(Marketwire – September 13, 2010) –  VHA Inc., the national health care network, announced today that it will offer a new leadership award to honor not-for-profit member hospitals that are leading the way in developing and implementing outstanding sustainability programs. 

“Most hospitals in the U.S. are intensely focused on the care they deliver to patients but not always as focused on the impact they have on the environment,” said Michael Regier, senior vice president of legal and corporate affairs at VHA. “However, due to heightened awareness and commitment to the global and local communities, a growing number of hospital leaders are looking at their organization’s environmental impact and they are doing some pretty amazing things about it. VHA plans to honor those leading hospitals and encourage others to step up.”

VHA will recognize hospitals that have:

• Shown a commitment to the development, implementation and promotion of a sustainability strategy
• Developed a “best in class” sustainability program, such as on-site programs to save energy, recycle, reduce waste or conserve water
• Measured and reported progress toward sustainability goals
• Demonstrated a commitment to increasing awareness of its sustainability story in the community and/or among its employees

The Sustainability Excellence Award is part of VHA’s existing Leadership Award series that honors hospitals for excellence in supply chain management, clinical care and community benefit leadership. The new award is also part of VHA’s larger commitment to recognizing and advancing innovative sustainability initiatives through its own Corporate Citizenship & Sustainability program. 

“VHA, Novation and Provista have taken significant steps that not only support our mission but also make a positive impact on our employees, our member health care organizations and the community around us,” said Terri Scannell, VHA’s director of corporate citizenship and sustainability. “We’re proud that VHA’s own CC&S program has twice received national recognition, and we are excited to introduce the VHA Sustainability Excellence Award that will recognize and applaud our members’ efforts and great work.”

The Sustainability Excellence award program is open to VHA hospitals that were active members in 2010 and that have developed organizational sustainability programs and initiatives. To enter, visit VHA’s Web site and download the Sustainability Excellence Award overview, criteria and application materials. Awards will be given in two categories — one for large IDNS and one for hospitals, and winners will be recognized at the 2011 Leadership Conference in San Diego. 

About VHA — VHA Inc., based in Irving, Texas, is a national network of not-for-profit health care organizations that work together to drive maximum savings in the supply chain arena, set new levels of clinical performance and identify and implement best practices to improve operational efficiency and clinical outcomes. Formed in 1977, through its 16 regional offices, VHA serves 1,400 hospitals and more than 30,000 non-acute care providers nationwide. VHA was ranked by Modern Healthcare as the 7th best place to work in health care in 2009. 

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Sept. 13, 2010) – GrowthPoint Capital Corp. (“GrowthPoint”) is updating its reporting of security holdings in Vigil Health Solutions Inc. (“Vigil”), as a result of the one for twenty consolidation of the common shares of Vigil effective at the opening of trading on September 10, 2010.

As announced by GrowthPoint on August 17, 2010, pursuant to a private agreement, it acquired ownership on July 27, 2010 of $100,000 in debt of Vigil. Post-consolidation this $100,000 is now convertible into, 500,000 common shares of Vigil at a conversion price of $0.20 per common share, representing approximately 10.0% of Vigil’s post-consolidation common shares.

In addition to this $100,000 in convertible debt following Vigil’s share consolidation (and the expiry of 288,000 options prior to the consolidation) GrowthPoint and its affiliates also hold 496,450 common shares representing approximately 9.9% of Vigil’s post-consolidation common shares; 32,500 Deferred Stock Units representing approximately 0.7% of Vigil’s post-consolidation common shares; and 22,800 Stock Options representing approximately 0.5% of Vigil’s post-consolidation common shares. In aggregate, assuming the full exercise and conversion of the aforementioned securities, GrowthPoint and its affiliates would hold approximately 21.0% of the issued and post-consolidation common shares of Vigil.

In addition to owning or exercising control over the Vigil securities through GrowthPoint Capital Corp., GrowthPoint acts jointly or in concert with Greg Peet and GrowthPoint Ventures (VCC) Corp.

GrowthPoint acquired these securities for investment purposes. GrowthPoint may, depending on market conditions and other factors as well as applicable securities laws, acquire additional securities of Vigil through the facilities of the TSX Venture Exchange, private agreements or otherwise. GrowthPoint may, depending on market conditions, sell any or all of its common shares of Vigil.

For additional information, or for a copy of the early warning report filed in respect of the above transaction, please please see contact information below.

ROCKVILLE, MD and SEOUL, KOREA–(Marketwire – September 13, 2010) –  Seegene today announced its successful initial public offering on the KOSDAQ (Korea Securities Dealers Automated Quotations). The company sold 636,500 shares for USD 26.16 (WON 30,500) each, raising USD 16.6 million and giving Seegene a market capitalization of USD 167 million. The company plans to invest the fresh capital in expanding its international market presence, with an emphasis on United States and Japan, where it is seeking regulatory approval for its portfolio of multiplex diagnostic PCR tests.

“This is an exciting day for Seegene, and marks a significant step toward our goal of being a leading global player in the molecular diagnostic industry,” said Jong-Yoon Chun, Chief Executive Officer of Seegene. “The capital that we raised will support the growing demand for our powerful multiplex diagnostic tests.”

Since 2007 Seegene has been growing sales at annualized growth rate of 170 percent. This rapid growth rate continues with sales of USD 9.5 million in the first half of 2010, compared to total 2009 sales of USD 11.2 million.

“Our products are defining a new category molecular diagnostics that are capable of simultaneously detecting multiple pathogens or genetic mutations in a single test. Using Seegene’s products, medical professionals are able to improve patient care by making accurate diagnoses faster, and more cost-effectively.”

The effectiveness of Seegene’s diagnostic testing technology was shown in the 2009 pandemic outbreak of (H1N1). While many molecular diagnostic firms responded to this flu outbreak by introducing individual kits that separately tested for each variant of Influenza A (H1, H3 , H5, and new H1N1), Seegene delivered a multiplex PCR test that simultaneously detected each flu subtype as well as the new H1N1 strain. Furthermore, the Seegene PCR test detected these strains with higher accuracy, specificity and sensitivity.

In July of this year at the AACC Clinical Lab Expo in Los Angeles, CA, Seegene introduced other multiplex molecular diagnostic tests — Magicplex™ and Anyplex™ — based on the company’s powerful READ™ (Real Amplicon Detection) technology:

Magicplex Sepsis, a multi-pathogen screening test that quickly and accurately identifies over 90 leading sepsis-causing pathogens, and Anyplex MDR-TB, a test that identifies Tuberculosis (TB) and genetic mutations causing TB resistance to the drugs isoniazid and rifampicin.

Chun added, “The market response to our READ technology and our new line of Magicplex and Anyplex tests has been extremely positive. We are in discussions with over 20 companies who are interested in licensing the technology or distributing these products in markets worldwide.”

“Later this year Seegene plans to introduce new Magicplex blood-screening and tumor detection tests, as well as a complete automated testing system. As we continue to grow our worldwide market presence, we will seek a NASDAQ listing after approximately three years,” he concluded.

About Seegene

Seegene, Inc. is a leading molecular diagnostics company developing, manufacturing and marketing innovative “multiplex” (or “multi-pathogen detection”) molecular diagnostic products and services. It holds proprietary technologies of both PCR and Real-time PCR named ACP™, DPO™, and READ™, which sets a standard in high-throughput and simultaneous multi-pathogen detection called “multiplex PCR.” The novel multiplex Real-time PCR technology, READ™, overcomes the limitations of conventional Real-time PCR, providing dramatic improvement in sensitivity and specificity. Seegene holds three novel Molecular diagnostic platforms: Seeplex® system adapting DPO™ Technology, Anyplex® and Magicplex® system which are Real-time PCR detection platform adapting DPO™ and READ™ Technology. Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene’s mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.

For more information please visit www.seegene.com or call +301-762-9066.

SANTA ANA, CA–(Marketwire – September 13, 2010) –  SixLog Corporation, an Astro Pak company providing on-site room disinfection and sterilization services, today announced it will showcase its revolutionary iHP™ (ionized Hydrogen Peroxide) technology at the American Society for Healthcare Environmental Services (ASHES) annual conference from September 27-28 at booth #536 at the Gaylord National Resort in National Harbor, Maryland.

SixLog provides room disinfection and sterilization services using its patented misting system to effectively eradicate microorganisms such as Clostridium difficile (C. diff), Vancomycin-resistant enterococcus (VRE), Methicillin-resistant Staphylococcus aureus (MRSA), Acinetobacter and other multi drug-resistant organisms (MDROs). This spore-killing iHP™ system is the next-generation of hydrogen peroxide fogging systems that successfully eliminates pathogens from all environmental surfaces and is faster and more cost effective than alternatives. SixLog’s room disinfection and sterilization services can easily augment hospitals’ terminal cleaning protocol and place current practices at the cutting edge of infection control. 

“I am excited to attend ASHES and demonstrate our new room sterilization technology,” says Vanessa Valdez, general manager of SixLog. “Environmental services (ES) departments across the nation are looking for innovative solutions to eradicate the growth of infection-producing organisms. SixLog’s iHP™ room sterilization technology enables ES professionals to quickly and effectively deploy a service that will have a fast impact on reducing the number of HAIs. We offer fully integrated and customized solutions for preventative room sterilization and/or outbreak control.”

In addition the proven efficacy of iHP™, it is also compatible with patient support equipment, including sensitive electronics, as it is noncorrosive. iHP™ leaves no residue behind, and upon completion, breaks down into just water and oxygen making it safe for staff, patients and visitors as well as the environment. A few examples of iHP™ room disinfection/sterilization applications include:

• Emergency and patient rooms
• Isolation rooms
• Intensive care units
• Surgical suites
• Tissue culture labs
• Bone marrow transplant suites
• Blood banks
• Sputum induction areas

For more information about SixLog’s iHP™ technology or to view it in action, please visit SixLog at booth #536 at ASHES 2010 during September 27-28 at the Gaylord National Resort in National Harbor, Maryland, or contact us at [email protected] or 877-4SIXLOG (474-9564).

About SixLog Corporation
SixLog provides on-site biological decontamination for equipment, rooms, entire buildings, and modes of transportation such as ambulances, trains, and cruise ships. Its proprietary iHP™ (ionized Hydrogen Peroxide) decontamination technology is utilized across a variety of industries including Life Sciences, Pharmaceutical, Healthcare, First Responders, Transportation, and Public Facilities. SixLog is privately held with headquarters in Santa Ana, CA. For more information, please visit www.sixlog.com.

Click here to see all recent news from this company

PEARL RIVER, NY–(Marketwire – September 13, 2010) –  Sanford “Sandy” Elsass, President of Uni-Ter Underwriting Management Corporation (UUMC), has been elected a Director of U.S. RE Companies, Inc., an international financial services and reinsurance brokerage firm, Tal P. Piccione, Chairman and Chief Executive Officer, announced.

UUMC is a subsidiary of U.S. RE Companies that builds and manages Risk Retention Groups in the healthcare industry. The RRGs provide general and professional liability insurance to long-term care facilities, physicians/surgeons, nurses, other healthcare professionals, and related businesses in 48 states. Elsass joined the U.S. RE Group in 2002. He also serves as a senior officer of U.S. RE.

“Sandy Elsass has built Uni-Ter into a major profit center. His rich experience in brokerage management and investment banking will be invaluable to our Board as U.S. RE grows,” Piccione said.

Elsass has been in the insurance industry and related business for 30 years. He serves currently as a Director of the Nevada Captive Insurance Association, the National Risk Retention Association, and Sunshine State Insurance Company of Florida. Prior to joining U.S. RE, he was an investment banker with Marsh Berry and Company. Earlier, he was President of Montgomery & Collins, a wholesale insurance broker that was sold to Marsh & McLennan. Elsass is a former Director of Wainwright Bank & Trust Company, Boston. He is a graduate of Ohio University.

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – September 13, 2010) –  FDAAdvisoryCommittee.com (FDAAC.com), a provider of live video webcasts of Food and Drug Administration (FDA) Advisory Committee meetings, today announced that it will webcast the Endocrinologic and Metabolic Drugs Advisory Committee’s discussions on the cardiovascular implications for Meridia® as well as the safety and efficacy of Lorqess®. The Meridia meeting is scheduled for September 15, 2010 from 8:00 a.m. ET to 5:00 p.m. ET. The Lorqess meeting will be held on September 16, 2010 from 8:00 a.m. ET to 5:00 pm. ET. 

On September 15, Abbott Laboratories’ new weight loss drug Meridia comes under review as experts discuss the results of clinical trials that evaluated the potential benefits of weight loss with the drug on major cardiovascular adverse events. Meridia acts as an appetite suppressant in combination with a diet and exercise regimen.

The Committee will review the safety and efficacy of Lorqess, Arena Pharmaceuticals’ new diet pill, on September 16. The drug acts as an appetite suppressant and works in conjunction with diet and exercise for obese patients as determined by body mass index (BMI).

Audience members, including biotech equity analysts, pharmaceutical employees, and journalists will be able to watch from anywhere in the world as the Committee reviews Meridia and Lorqess. FDAAC.com will webcast the meeting live and on location from the Inn and Conference Center at the University of Maryland University College.

FDAAC.com is committed to delivering the highest quality of video and experience. By utilizing h.264 encoding in conjunction with Flash Media, FDAAC.com’s webcasts deliver a near instantaneous stream. These high-quality streams can be accessed from anywhere around the globe and are archived for six months after the live event for unlimited review.

FDAAC.com‘s webcasts are powered by TalkPoint, a provider of Web-based audio and video Webcasting solutions and services. With over a decade of experience, TalkPoint has developed the most robust, scalable, interactive webcasting platform in the industry. TalkPoint’s easy-to-use applications incorporate audio, video, slides, and other interactive elements to deliver high-impact webcasts cost-effectively.

To join the webcasts on September 15 and 16 at 8 a.m. ET register at http://fdaac.com

About FDAAdvisoryCommittee.com
FDAAC.com provides live video webcasts of FDA Advisory Committee meetings captured on location. These meetings cover an array of topics related to medicinal health including OTC, prescription and treatment devices. Very often meetings will result in rulings on clinical trials, final approval and bans of medications and treatment options. TalkPoint is the exclusive webcast provider for FDAAdvisoryCommitte.com.

For more information on FDAAC.com, go to www.fdaac.com.

PORT HUENEME, CA–(Marketwire – September 13, 2010) –  (TSX-V: KLH) (PINKSHEETS: SBOTF) — Stellar Biotechnologies, Inc. is collaborating with Bayer Innovation GmbH (BIG) in the development of biopharmaceuticals. Bayer’s personalized idiotype vaccine for the treatment of Non-Hodgkin’s-Lymphoma (NHL) is currently in Phase I clinical trials, and the cooperation is related to the development of a personalized Non-Hodgkin’s-Lymphoma vaccine. The vaccine antigen is produced in tobacco plants based on Bayer’s proprietary magnICON^® technology. Bayer Innovation GmbH is a wholly-owned subsidiary of Bayer AG (PINKSHEETS: BAYRY) (XETRA: BAYGN) (LSE: BYRB).

A critical project feasibility milestone in the “Joint Development Agreement” has been achieved. Under terms of the agreement, Stellar Biotechnologies supplies Keyhole Limpet Hemocyanin (KLH) which is coupled to the idiotype protein produced in tobacco plants. KLH is a highly potent immuno-stimulatory protein, which stimulates the lymphocytes to recognize even familiar proteins attached to it as foreign. During the immune response that ensues, the lymphocytes mainly focus on the peptide sequence of the attached tumor idiotype. This so-called immunogenic carrier molecule comes solely from the rare keyhole limpet, and Stellar has technology for the maintenance of the animal, the non-lethal extraction of the critical molecule and a profitable refinement process of KLH.

By consent of both parties, Stellar will receive a milestone payment from BIG, and the co-development agreement is being expanded and continued to achieve important new endpoints that may prove critical to Bayer’s interest in therapeutic vaccines based on its plant-based protein expression system, the magnICON® technology.

Dr. John Butler, Global Project Leader of Plant Made Pharmaceuticals (PMP) for Bayer, said, “We are happy to have achieved this important milestone, and appreciate working with Stellar’s talented scientific team, led by Professor Daniel Morse. Together with Bayer’s scientists and engineers, we believe we have made a significant impact on the potential cost structure as well as efficiency and sustainability of our vaccine production. Securing a long-term sustainable KLH supply is a key element in our efforts to enable a new therapy that could significantly benefit disease outcomes and quality of life of NHL patients.”

Frank Oakes, CEO of Stellar, said, “Stellar has been honored by the opportunity to partner with the cutting-edge team at Bayer Innovation, and now, to grow this new relationship to the next level. Bayer Innovation is among the highest regarded participants in the PMP field, and we believe the credibility that comes from working with an internationally recognized biotechnology, materials science, and pharmaceutical powerhouse is incalculable. We are excited by the opportunity for growth in this relationship, and the potential for exploring future business development opportunities with Bayer Innovation.”

About Bayer Innovation GmbH (BIG — http://www.bayer-innovation.com/en/homepage.aspx) is part of Bayer’s innovation strategy and complements the innovation activities of the different subgroups in the fields of health care, nutrition and high-quality materials. Its objective is to identify and develop new growth opportunities, preparing entry into new and expanding markets. Currently the focus is on medical technology and the production of plant-made pharmaceuticals.

About Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) (www.StellarBiotechnologies.com) is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This ancient evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.

Statements in this press release other than purely historical factual information, including statements relating to revenues or profits, or the Company’s future plans and objectives, or expected sales, cash flows, and capital expenditures constitute forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company’s business, including risks inherent in the technology history. There can be no assurance that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company’s securities set out herein in the United States, or to, or for the benefit or account of, a U.S. person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

JERICHO, NY–(Marketwire – September 13, 2010) –  SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (“TRDX” or the “Company”) (PINKSHEETS: TRDX) today announces that it believes that the future looks very bright for itself and its sublicense partner, Montreal-based Genesis Biopharma, Inc., as they continue making progress regarding their new compound in development for the treatment and potential cure of Painful Diabetic Neuropathy (PDN).

According to the International Diabetes Federation the global health expenditure on diabetes is expected to total at least USD 376 billion in 2010 and USD 490 billion in 2030. (http://www.idf.org/webdata/docs/PIIS0168822710000495.pdf)

Back in 2003 the American Diabetes Association estimated that in the U.S. the total annual cost of treating diabetic peripheral neuropathy and its complications was $10.91 billion. (http://care.diabetesjournals.org/content/26/6/1790.full)

ABOUT PDN:

PDN is one of many complications of diabetes. Forty to fifty percent of diabetic patients may develop PDN over 15 to 20 years. PDN is present in 11.6% of patients with Type I diabetes and 32.1% of patients with Type II diabetes. PDN may present itself as a progressive build-up of unpleasant sensory symptoms including tingling (paraesthesia), burning pain, radiating pain down the legs and toes and lancinating or contact pain. The pain is more severe during the night and often prevents sleep. Some patients may be in a constant state of tiredness because of sleep deprivation while others are unable to maintain employment.

1. According to the World Health Organization there are approximately 220 million people worldwide who have diabetes

   (http://www.who.int/mediacentre/factsheets/fs312/en/). In the U.S., according to the 2007 National Diabetes Fact Sheet, a total of 23.6 million had diabetes of which 17.9 million were already diagnosed and the rest, 24%, were undiagnosed.

   (http://www.diabetes.org/diabetes-basics/diabetes-statistics/). If you add the undiagnosed cases to the 220 million reported by the World Health Organization the total number could exceed 270 million worldwide.

2. Diabetic neuropathy can cause nerve damage in the feet that leads to decrease or loss of sensation. As a result, a blister or a cut can go unnoticed. Any infection that might ensue can result in tissue death (gangrene) and in some cases severe damage can lead to amputation of toe, foot or even leg. Each year about 80,000 – 84,000 amputations are performed in the U.S. alone (See Diabetes-Related Amputation Statistics:
   http://www.isletsofhope.com/diabetes/complications/amputation_1.html#diabetes).

   How many of these amputations could have been avoided had a solution been made available?

Mr. Leo Stella, CEO of Genesis, has stated: “Until now, there is absolutely no mechanism based treatment that can reverse neuropathy associated with diabetes. Drugs exist that have a temporary effect on the pain, but these drugs cannot cure the cause. The goal of Genesis Biopharma is to develop a drug that will cure this terrible condition.”

Dr. Jan Stahl, CEO of TRDX, commented: “The opportunity is very significant for all the stakeholders in this PDN solution. We will continue our efforts to make this potential cure a reality and deliver quality value for our shareholders.”

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. (www.genesisbiopharma.com) is a Canadian corporation founded in 2007 to exploit the commercial potential for the therapeutic use of peptidomimetic (modified amino acid peptides) compounds. Amino acids are the building blocks of proteins, which are found in every cell. Proteins consist of extremely long and complex amino acid chains. In contrast, a peptide is a short string of amino acids, joined by chemical bonds (also called “amide bonds”).

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company’s business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

JERICHO, NY–(Marketwire – September 10, 2010) –  SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (“TRDX” or the “Company”) (PINKSHEETS: TRDX) today confirms it has completed the structuring of DiabetRX Pharma Corp. (“DiabetRX”) which will be assigned the Sublicense and upon Final Closing will be 100% owned by TRDX.

In addition, the Company provides the following details regarding the recently executed Definitive Sublicense Agreement (“Definitive”) with Montreal-based Genesis Biopharma, Inc. (“Genesis”).

Dr. Jan Stahl, CEO of TRDX, commented: “Since the signing of the Definitive Agreement, I am very happy with the progress we have made with Genesis. We feel confident in the current steps we are taking to complete the Initial Closing and first Tranche financing. We view DiabetRX as a long term investment with large potential and look forward to the Final Closing.”

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. (www.genesisbiopharma.com) is a Canadian corporation founded in 2007 to exploit the commercial potential for the therapeutic use of peptidomimetic (modified amino acid peptides) compounds. Amino acids are the building blocks of proteins, which are found in every cell. Proteins consist of extremely long and complex amino acid chains. In contrast, a peptide is a short string of amino acids, joined by chemical bonds (also called “amide bonds”).

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company’s business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

PT. HUENEME, CA–(Marketwire – September 10, 2010) – Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) announces filing for patent protection of inventions related to its native Immunogenic (IMG) KLH technology platform and immune status monitoring product portfolio. KLH (keyhole limpet hemocyanin) is presently the most pharmaceutically important ICP (immune carrier protein) and IMG KLH is the most effective immune stimulant for use in cancer, viral and parasite vaccines; animal vaccines; and diagnostic products. Patent claims include pharmaceutical grade compositions of matter, processes for manufacture and methods of use in a wide range of therapies.

John Sundsmo, Ph.D., VP Research and Intellectual Property, said, “With filing of this patent application Stellar has achieved an important milestone on the road to becoming the preeminent world leader in development and manufacture of pharmaceutical grade immune carrier proteins. We are very pleased with the progress achieved by our scientists and what this patent application tangibly demonstrates.”

Corporate Website: www.StellarBiotechnologies.com
Stellar News at Marketwire: http://www.marketwire.com/mw/search.do?params=&grpSearch=C&companyid=70788

About Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) – (www.StellarBiotechnologies.com): is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This ancient evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company’s securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

TAMPA, FL–(Marketwire – September 10, 2010) –  Sage North America today announced that the Sage Healthcare Division, a leading provider of electronic health records (EHR) and practice management software, has been named a preferred vendor by the Massachusetts eHealth Institute to make available the Sage Intergy Meaningful Use Edition to all of the institute’s thousands of participating healthcare providers.

Massachusetts eHealth Institute is part of an extensive network of 60 Regional Extension Centers (RECs) across North America that serves as a neutral source for EHR and health information technology (HIT) as providers seek to navigate EHR options and select vendors that meet meaningful use requirements. Massachusetts eHealth Institute performed an exhaustive analysis of vendors in the HIT landscape prior to recommending solutions to its physician base.

“We are pleased to have Sage join our select list of certified health IT companies that will help thousands of health care providers across Massachusetts successfully transition to electronic health records,” said Rick Shoup, Ph.D., Director of the Massachusetts eHealth Institute. “Widespread deployment of electronic health records leads to better quality care for patients, reduces health care costs and spurs new jobs in the health care industry.”

Sage Intergy line of products and services met Massachusetts eHealth Institute’s standards for quality. By implementing a fully automated EHR such as Sage Intergy, providers will be better able to achieve meaningful use.

Through the partnership, Sage will support Massachusetts eHealth Institute’s goal to increase quality of care and improve public health.

“Being named a preferred vendor by the Massachusetts eHealth Institute means Sage will continue to provide physicians within the state with IT solutions and support as they move toward meaningful use and into the new healthcare economy,” said Ken Ernsting, Vice President of Business Development for Sage Healthcare Division. “We’re proud to serve medical professionals in Massachusetts, and aligning with this leading health organization.”

Clinics eligible to utilize Massachusetts eHealth Institute’s subsidized services include Priority Primary Care Providers (PPCP) in the area of family medicine, obstetrics, and gynecology, general internal or pediatric medicine. In addition, practices must be either individual or a small group practices (defined as 10 or fewer professionals with prescriptive privileges in the practice) primarily focused on primary care; public and critical access hospitals; and community health centers and rural health clinics.

About Massachusetts eHealth Institute
The Massachusetts eHealth Institute (MeHI), a division of the Massachusetts Technology Collaborative, is the state-designated entity for health care innovation, technology and competitiveness. Established by Governor Patrick and the Massachusetts Legislature in Chapter 305 of the Acts of 2008, MeHI is responsible for advancing the dissemination of health information across the Commonwealth, including the deployment of EHR systems in all healthcare provider settings that are networked through a statewide HIE. For more information on MeHI, go to www.maehi.org. 

About Sage Healthcare Division
Sage Healthcare Division provides integrated electronic health records, EDI applications and practice management systems to approximately 80,000 physicians and thousands of ambulatory care practices throughout North America. These systems enable physicians and practice managers to better manage their practices and improve profitability. Sage Healthcare Division is based in Tampa, Fla., and is a division of Sage North America. For more information, please visit www.sagehealth.com or call (877) 932-6301.

About Sage North America
Sage North America is part of The Sage Group plc, a leading global supplier of business management software and services. Sage North America employs 4,000 people and supports 3.1 million small and midsized business customers, including medical practices in the United States. The Sage Group plc, formed in 1981, was floated on the London Stock Exchange in 1989 and now employs 13,100 people and supports 6.2 million customers worldwide. For more information, please visit the Web site at www.sagenorthamerica.com.

© 2010 Sage Software, Inc. All rights reserved. Sage, the Sage logos, and the Sage product and service names mentioned herein are registered trademarks or trademarks of Sage Software, Inc. or its affiliated entities. All other trademarks are the property of their respective owners.

LOS ANGELES, CA–(Marketwire – September 10, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (www.mmrglobal.com) announced today the formal launching of a new department, MMRGlobal Travel and Benefits Sales Group. The group will be headed by Patrice A. Shilling, newly named Vice President, Global Travel and Benefit Sales. Shilling is an experienced travel executive who has worked in senior management positions at Travelocity Business, American Express, Alitalia Airlines and Le Méridien and whose clients have included Samsung, McKesson, Medtronic, Accenture, UBS, Boston Scientific and Liberty Mutual, amongst numerous other Fortune 500 and 1000 companies.

Robert H. Lorsch, MMRGlobal Chairman and CEO, said, “Patrice Shilling will lead an initiative to sell our branded Personal Health Record (PHR) (www.mmrvideos.com) and MyEsafeDepositBox products to travel procurement groups and employers with the emphasis on how they add to the safety and security of employees who travel globally, particularly expats. Our strategy will also include targeting organizations like ADP who work regularly with human resources executives and corporate purchasing departments.”

Shilling said, “Our plan envisions selling through corporate procurement, human resources and risk management, as these are untapped channels. Opportunity exists to establish strategic partnerships and alliances with online technology companies, including associations, financial and affinity groups, reward programs and travel providers such as my previous employers American Express and Travelocity Business.”

About MMRGlobal, Inc.
MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mymedicalrecords.com and view the videos at www.mmrtheater.com.

Forward-Looking Statements
Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements, and some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue,” or the negative of such terms and other comparable terminology. MMRGlobal, Inc. disclaims any intent or obligation to revise or update any forward-looking statements. These forward-looking statements are based on MMRGlobal, Inc.’s reasonable expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related to changes in MMRGlobal, Inc.’s business prospects, results of operations or financial condition, government regulation, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.’s public filings with the U.S. Securities and Exchange Commission.

Click here to see all recent news from this company

MADISON, WI–(Marketwire – September 10, 2010) –  TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for cancer care, today announced that CFO Thomas Powell and Vice President of Operations and Business Development Eric Schloesser will present at Baird’s 2010 Health Care Conference on Wednesday, September 15, 2010 at 11:00 a.m. ET. The conference will be held at the St. Regis New York Hotel in New York City, N.Y.

A live audio Webcast of the presentation will be available on the investor relations page of TomoTherapy.com. For those who are unable to listen to the live presentation, an archive of the Webcast will be available on the company’s site for 30 days following the presentation.

About TomoTherapy Incorporated 
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile^™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

MUNDELEIN, IL–(Marketwire – September 9, 2010) –  As part of Medline’s ERASE CAUTI™ program, created to help clinicians reduce the risk of urinary catheter-associated infections, the company today announced the launch of a pediatric catheter tray designed to help clinicians better perform and manage urinary catheterizations for children. The new tray introduces “Buddy the Brave,” a friendly, upbeat animal character, to help younger patients better manage the catheter process. Buddy is featured on the tray’s packaging, in a children’s activity card and on a bravery sticker.

“Our ‘Buddy the Brave’ character and related materials may help children focus their attention away from the procedure, which will help them to tolerate what can be an unpleasant experience,” said Alecia Cooper, senior vice president of clinical services for Medline. “The ERASE CAUTI system combines evidence-based principles and training with a revolutionary-designed tray to assist the clinician in using a proven and safe method for catheter insertion and maintenance.”

In a survey done on 110,709 pediatric ICU patients, 6,290 healthcare-associated infections were noted. The top three major sites of infections, accounting for 64% of all healthcare-associated infections, were bloodstream infections (28%), pneumonia (21%), and urinary tract infection (15%). Each of these infections was strongly associated with use of an invasive device.¹

The new pediatric tray is the latest addition to Medline’s ERASE CAUTI product line. Similar to the adult version, the new pediatric tray features an innovative one-layer design. The one-layer design (versus the industry norm of two layers) supports and encourages a logical “best practices” sequence of events during catheterization that helps the provider adhere to current recommended healthcare practices. The new tray design is intuitive, reduces variance in care process and promotes efficiency.

Other features of the ERASE CAUTI pediatric catheter tray system include:

Clear photography of tray contents. In Medline’s new pediatric Foley catheter tray, the product instructions and clear color images are located on the outside to encourage clinicians to review the information before they start. To help identify the contents of the kit, the label features an actual color photo of the tray components, including a picture of Buddy the Brave that easily identifies the product as a pediatric tray. The photo can also be used to discuss the procedure with the patient and parent. The outer label opens like a book and on the inside is a clear, step-by-step instructional guide to catheter insertion.

Checklist that helps practitioners “do the right thing.” The outer label contains “trigger tools,” according to Cooper, to promote the recommended guidelines from the Centers for Disease Control and Prevention (CDC). A checklist of clinical indications for catheterization is printed on a peel-off sticker. The checklist is formatted to easily fit in the patient chart or medical record. It is also available in an electronic format for electronic documentation.

Buddy the Brave Activity Card and family education resource. To keep young patients distracted from the medical procedure, an activity card is included in the tray. The card includes a story featuring Buddy the Brave, a word find game and a maze. The activity card also provides useful family education on urinary catheters and the catheterization process.

Competency validation tools. A key component to the effectiveness of the ERASE CAUTI program is the cutting edge online competency and measurement tools that assess and sustain staff results. The interactive competency programs are available on Medline University, Medline’s online education resource. They are available to staff anytime and can be easily incorporated into the annual skills competency program for a facility’s nursing staff.

About Medline Industries, Inc.
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

WINCHESTER, CA–(Marketwire – September 9, 2010) –  James Bertalotto of Springdale, Arkansas was the door gunner and crew chief of a Huey helicopter in Vietnam. He served two tours from 1966-1969. “When you’re the crew chief and you are assigned to a helicopter, you go wherever that ‘copter goes. It’s like a cowboy and his horse.” For Bertalotto, that helicopter took him into some life experiences that caused trauma which to this day he still has trouble overcoming. After all these years the Vietnam War still rages within him. “Not all wounds are visible,” said Bertalotto. Still, he tries to cope. He says he receives excellent care at the Fayetteville VA Medical Center where he goes for therapy twice a week. It was during a therapy session that Bertalotto was first introduced to the Help Hospitalized Veterans (HHV) arts & crafts program.

Bertalotto said, “I have a wife of 40 years, two children and five grandchildren and they are the love of my life. I started working on the HHV craft kits about three years ago and really enjoy working on them. I get about three or four a year and work on them with my grandchildren. It’s a special time to share with them… to listen, laugh and share a hug.” Bertalotto recently worked on one of HHV’s newest kits — the Veterans Pride Desktop Flag kit. “We were all so proud of the flags in the kit that I instructed my grandkids to put it on my casket when I pass away,” he added. Bertalotto says working on the craft kits takes his mind away from his troubling thoughts. “The kits bring a level of enjoyment into my life I wouldn’t have otherwise, but the hugs are the best part of working on them. That’s the best medicine of all.”

HHV is the largest supplier of free therapeutic arts & crafts kits to VA and military hospitals worldwide. For more information on HHV products and services, please visit www.hhv.org or call 1-888-567-VETS.

Documents and/or Photos available for this release:

PDF_of_release

To view supporting documents and/or photos, go to www.enr-corp.com/pressroom and enter Release ID: 269831

WEST HARTFORD, CT–(Marketwire – September 9, 2010) –  ORLive, the leader in online medical video, presents a live interactive broadcast focusing on the use of artificial disc treatments for cervical disease. In addition ORLive invites you to take part in the latest installment of the Virtual Brain Tumor Board, and wraps up our back to school focus with three new educational video referrals.

NEW ON ORLIVE

LIVE VIDEO — Artificial Disc Treatments for Cervical Disease
Live Thursday, September 9, at 7:00PM

Until recently, spinal fusion was the surgical solution to cervical disc disease. ORLive invites you to watch footage of an Artificial Discectomy performed by William Kuhn, MD of Halifax Hospital, and join in on a live online discussion with the doctor and patient, Ali Rabatsky. 

Viewers of this video are invited to interact with the team via the ORLive website, where you can also request a reminder to alert you when this video is going live.

ORLIVE REFERRALS – Week of September 5, 2010
Each week ORLive highlights on-demand videos for our membership and visitors. 

Medical Education Referral: Defining and Treating Chronic Pain from Beth Israel Hospital in New York City.

CME Referral: The Science and Medicine of Parkinson’s Disease from CMEducation Resources.

Viewer’s Referral: Landmark Practice Advances in STEMI and ACS from CMEducation Resources.

HIGHLIGHTS

NOW ON-DEMAND — Surgical and Medical Treatments for Type 2 Diabetes
Now Available On-Demand

Type 2 diabetes can lead to potentially deadly complications for many patients, but the team at NewYork-Presbyterian remains on the forefront of research and treatment innovations. Join Dr. Francesco Rubino, Chief, Gastrointestinal Metabolic Surgery at the Weill Cornell Medical Center, Dr. Judith Korner, from Columbia University Medical Center, and Dr. Louis Aronne, from the Weill Cornell Medical Center, as they review the advancements that are being made and see what happens when gastric bypass surgery results in a possible remission of diabetes.

Viewers of this video can still interact with the team via the ORLive website, where you can also request updates as they become available.

FEATURED CHANNEL — Sorin Group
With over 40 years of experience, Sorin Group is responsible for many of the innovations that have made heart valve replacement and repair among the safest and most effective procedures in the world today. ORLive invites you to watch and learn as Sorin presents video of many of these devices on the Sorin ORLive Channel. 

PREVIEW — Continuum® Acetabular System and Zimmer® M/L Taper with Kinectiv® Technology
Premieres Thursday, September 23, 2010 at 7PM EDT

On Thursday, September 23rd at 7PM EDT Zimmer Medical Education will broadcast an ORLive Total Hip Arthroplasty featuring the Continuum Acetabular System and the Kinectiv Modular Neck Technology. The surgery will be performed by Dr. Mark Hartzband, Hartzband Center for Hip and Knee Replacement, L.L.C., Paramus, NJ and will be moderated by Dr. Paul Duwelius, St. Vincent Hospital, Portland, OR. The broadcast will last one hour and will show the entire surgical procedure. Following the live broadcast the surgery will be archived for future playback.

This opportunity allows for firsthand insight of the safe and effective implantation and surgical procedure involved with the Continuum® Acetabular System and the Zimmer® M/L Taper with Kinectiv® Technology.

This surgery video is available exclusively to members of the ORLive community, and members can interact and ask questions via the ORLive website. Learn more about this broadcast or get a reminder at ORLive.com, and be ready to view this exciting procedure by activating your free membership to ORLive today.

About ORLive
ORLive is the leading provider of video communication channels to the healthcare community. Working collaboratively with hospitals and device manufacturers, ORLive produces and distributes customized, interactive, video programs that demonstrate the latest advances in medicine, surgical techniques and product innovations. The ORLive broadcasting network provides an intimate look at over 650 live and on-demand surgeries to a global audience, streaming over 50,000 hours of programming each month. The ORLive network can be found on-line at www.ORLive.com.

id=”nav_links”>

VICTORIA, BRITISH COLUMBIA–(Marketwire – Sept. 9, 2010) – Vigil Health Solutions Inc. (“Vigil”) (TSX VENTURE:VGL)today announced that, effective the opening of trading on September 10, 2010, Vigil’s common shares will be consolidated on the basis of one post-consolidation common share for each twenty pre-consolidation common shares. The consolidation was approved at Vigil’s Annual General and Special Meeting of shareholders held on August 24, 2010. Vigil currently has 100,046,135 pre-consolidation common shares outstanding. Vigil will have approximately 5,002,310 post-consolidation common shares outstanding. Vigil’s name and trading symbol on the TSX Venture Exchange will not be changed in connection with the consolidation.

KYLE, TX–(Marketwire – September 9, 2010) –  CommuniCare Health Centers, a Federally Qualified Health Center that provides health care in Bexar and Hays Counties, announced today that it has received a $56,533 grant from the Austin Affiliate of Susan G. Komen for the Cure®. The grant will provide low-income, uninsured women in Hays County with greatly needed educational information about breast cancer, access to clinical breast exams, and mammograms.

“We are so pleased to receive the grant from the Austin Affiliate of Susan G. Komen for the Cure® and look forward to making breast health services available to more women in Hays County,” said Debbora A. Thompson, Chief Executive Officer of CommuniCare Health Centers. “Without organizations like the Komen Foundation many low-income, minority, uninsured women would not have access to critical breast health screenings.”

The services provided by the grant will be offered to uninsured women aged 40 to 64 at CommuniCare’s health center at 1340 Wonder World Drive in San Marcos and at its new health center in Kyle, CommuniCare Health Centers – Kyle at 2810 Dacy Lane. To access services funded by this grant, please call 512.392.1718. CommuniCare will be opening CCHC-Kyle, on September 20, 2010 where medical, dental and behavioral health care will be available to area residents. 

About the Austin Affiliate of Susan G. Komen for the Cure:
The Austin Affiliate of Susan G. Komen for the Cure® has been working to better the lives of those facing breast cancer in the Greater Austin community since 1999. Through events such as the Komen Austin Race for the Cure® and other philanthropic endeavors, the Austin Affiliate has invested nearly $7 Million in community breast health programs in Bastrop, Caldwell, Hays, Travis, and Williamson Counties. The Affiliate makes grants to local hospitals and community organizations that provide breast health education and breast cancer screening and treatment programs for medically underserved women.
For more information on the Austin Affiliate of Susan G. Komen for the Cure® please visit www.komenaustin.org.

About CommuniCare:
CommuniCare Health Centers (CCHC) has served San Antonio for over 38 years. CCHC provides medical, dental and behavioral health services to uninsured and underserved residents in Bexar and Hays counties and delivered more than 151,000 visits in 2009 in two health centers in San Antonio and one in San Marcos. As a non-profit community health center, it serves those with Medicaid, Medicare, medical insurance and those that do not have insurance, charging on a sliding-fee scale based on annual household income and family size. For more information on Barrio Comprehensive Family Health Care Center, Inc. dba CommuniCare Health Centers please visit www.communicaretx.org.

DENVER, CO–(Marketwire – September 9, 2010) –  The Breakaway Group will host an exclusive group of healthcare leaders, educators and innovators at the Inverness Hotel & Conference Center in Denver, from September 23-25, for the 2010 Healthcare Forum: Beyond Implementation, The New Leadership Agenda for Lasting EMR Adoption. Featuring a presentation by Wil Yu, Special Assistant, Innovations and Research, Strategic Health IT Advanced Research Projects, Office of the National Coordinator for Health IT, the central theme of the forum centers on the changing leadership agenda for three roles in healthcare: the CEO, CIO and Clinical Leadership.

Attendees and presenters include top leaders from Trinity Health, UT Medical Group, Arkansas Children’s Hospital, Baptist Health System and Hartford Health Care, and others. The 2010 Healthcare Forum continues the conversation launched in 2007 at the Healthcare Summit in Vail, Colo., where discussion focused on the challenge of how to treat an HIT implementation as more than a single event. 

“The Healthcare Forum provides a way for C-level executives to collaborate on finding successful ways to shift leadership priorities, to refocus organization efforts around EMR adoption,” said Charles Fred, chief executive officer of The Breakaway Group. “We are excited to offer the results of our research as a way to facilitate meaningful use and sustainable EMR adoption in the healthcare industry.” 

Recent Research Serves as Foundation for New Leadership Agenda
In the face of increased pressure to adopt new technology, healthcare executives have been led to reprioritize their everyday roles. Recent in-depth research from The Breakaway Group into the major barriers of EMR adoption and improved clinical outcomes (Beyond Implementation: A Prescription for Lasting EMR Adoption, 2010, Haugen, H., Woodside, J.) will serve as a foundation for the leadership agenda discussion. 

The authors, Dr. Heather Haugen and Dr. Jeffrey Woodside, M.D., conducted more than 18 months of research with leaders and healthcare organizations representing more than 3,200 physicians and 350 ambulatory sites. Through case studies and research, they examine why the transition to EMR is often overly costly, lengthy and frustrating.

“Despite the significant benefits of electronic medical records, healthcare organizations are not seeing the financial and clinical outcomes they had hoped for,” said Dr. Haugen, co-author of Beyond Implementation. “After investigating the outcomes of poor adoption and why physicians don’t get the full potential from EMR, we have identified one common thread. Too often, the primary focus is on go-live implementation when instead, this step should be the beginning of a sustained effort for the life of the application.”

About The Breakaway Group
The Breakaway Group helps healthcare providers quickly adopt new technology through a research-based method that uses innovative simulations and coaching to help improve patient care and safety. The firm’s unique approach to learning is based on the best-selling book “Breakaway” by CEO and Founder Charles Fred. For more information, visit www.thebreakawaygroup.com.

PT. HUENEME, CA–(Marketwire – September 9, 2010) –  Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) announces filing for patent protection of inventions related to its native Immunogenic (IMG) KLH technology platform and immune status monitoring product portfolio. KLH (keyhole limpet hemocyanin) is presently the most pharmaceutically important ICP (immune carrier protein) and IMG KLH is the most effective immune stimulant for use in cancer, viral and parasite vaccines; animal vaccines; and diagnostic products. Patent claims include pharmaceutical grade compositions of matter, processes for manufacture and methods of use in a wide range of therapies.

John Sundsmo, Ph.D., VP Research and Intellectual Property, said, “With filing of this patent application Stellar has achieved an important milestone on the road to becoming the preeminent world leader in development and manufacture of pharmaceutical grade immune carrier proteins. We are very pleased with the progress achieved by our scientists and what this patent application tangibly demonstrates.”

Corporate Website: www.StellarBiotechnologies.com
Stellar News at Marketwire: http://www.marketwire.com/mw/search.do?params=&grpSearch=C&companyid=70788

About Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) – (www.StellarBiotechnologies.com): is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This ancient evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company’s securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

MADISON, WI–(Marketwire – September 9, 2010) – TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced, integrated radiation therapy solutions for cancer care, today announced that its technology will soon be used to treat cancer patients in Nottingham, England. The Nottingham Radiotherapy Centre will install the TomoTherapy^® Hi·Art^® treatment system in November as part of a service expansion and relocation. 

The TomoTherapy treatment system enables delivery of state-of-the-art CT image-guided intensity modulated radiotherapy (IG-IMRT), enabling the hospital to reinforce its leadership in high-quality, efficient cancer care for the people of the East Midlands of England.

The Nottingham Radiotherapy Centre serves a population of approximately 1 million and delivers 37,000 fractions of radiation therapy annually. The Centre provides complex external beam treatment including paediatric radiation therapy, intensity-modulated radiation therapy (IMRT), continuous hyperfractionation, and total body electron and photon radiation therapy. The centre is part of Nottingham University Hospitals National Health Service (NHS) Trust, which is one of the country’s largest teaching hospitals.

Russell Hart, Radiotherapy Service Manager of the Centre, states:

“Our multi-disciplinary team is thrilled to be introducing TomoTherapy technology. Benefits will include better access for our patients to what we believe is the best delivery system for complex image-guided, intensity-modulated radiation therapy (IG-IMRT). The new machine will also mean that there will be some patients for whom curative treatment will now be possible whereas in the past treatment would only have been offered on a palliative basis. A clear advantage of the TomoTherapy system is the rapid installation time. This will enable us to have the high technology available in a short space of time — much quicker than a conventional linear accelerator.

Here at Nottingham, in line with national policy, we believe that four-dimensional (4D) Adaptive Radiotherapy is the future standard of care for radiotherapy treatment, and that the TomoTherapy Hi·Art system is the most sophisticated and best system to achieve this objective. We believe our equipment strategy will provide us with a full range of treatment options for the population we serve, with the TomoTherapy system best able to deliver the most complex dose distributions.”

Commenting on the key role TomoTherapy technology is playing in a publicly funded health service, Julie Mead, Director and Clinical Advisor from Oncology Systems Limited, states:

“The oncology team at Nottingham put all equipment vendors through a rigorous clinical and technical public tender evaluation. They clearly concluded that the TomoTherapy platform would bring significant benefits to a centre that is reported as having one of the busiest patient throughput figures per treatment machine, in all of the UK. Already having a linac IMRT programme in place, the Nottingham Radiotherapy Centre also saw the improvement in treatment quality that TomoTherapy technology would bring, along with centre-wide efficiency gains from allocating advanced treatments to the unit. In difficult financial times, the TomoTherapy platform offers not only the best quality radiotherapy, but also the highest efficiency for advanced IG-IMRT. The NHS looks at cost-effectiveness as a key criterion. The TomoTherapy platform fits the bill.”

Reinforcing the efficiency requirements so critical to the publicly funded NHS, Nottingham’s Russell Hart adds:

“We treat between 35 to 50 patients per normal working day on our linear accelerators, depending on the complexity of the work being undertaken. We aim to maintain that throughput and utilise TomoTherapy technology to its maximum, by treating up to 35 patients per day. Other NHS TomoTherapy customer sites have demonstrated that this is possible in the UK, but of course this will be a tremendous achievement in Nottingham as we clearly expect that the treatments delivered on the TomoTherapy unit will have far higher quality and complexity than what is feasible on the linear accelerator it is replacing.”

TomoTherapy technology is developed and manufactured by TomoTherapy Inc., and is supplied in the UK by Oncology Systems Limited, based in Shrewsbury, England.

About Nottingham University Hospital
Nottingham City University Hospital NHS Trust (NUH) is one of England’s busiest and largest acute teaching trusts. It provides acute and specialist services to 2.5 million people within Nottingham and surrounding communities from the Queen’s Medical Centre and the City Hospital campuses. The hospital’s annual budget is in excess of £682 million of public sector funding, housing over 1,700 hospital beds and employing over 13,000 staff.

Nottingham is the only city in the country to secure three successful bids for prestigious biomedical research units. NUH is working with The University of Nottingham to help to translate research findings for stomach, bowel and liver disease, hearing and respiratory disease into better patient care.

About Oncology Systems Limited
Oncology Systems Limited (OSL) is a privately owned limited company based in Shrewsbury, England. OSL is an exclusive supplier of radiation therapy technology to the UK and Ireland. It distributes TomoTherapy^® cancer treatment technology to the UK’s NHS and private radiotherapy facilities, and to both public and private providers in the Republic of Ireland.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile^™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

SCOTTSDALE, AZ–(Marketwire – September 9, 2010) – Top 10 women’s health site EmpowHER today launched what is expected to be the largest online movement for women’s health in the next year — the 1000Women campaign.

Expecting to engage 1,000 women who will each recruit another 1,000 women to participate in this classic pay-it-forward viral effort; the campaign’s goal is to get 1 million women to share their inspirational health stories with friends, family, and women they’ve never even met. Campaign participants can do this by creating profiles on 1000Women.com where they can: “tell a friend” about the campaign; share their own personal health and wellness story — including pictures and videos if they wish, or simply vote for another woman’s story that inspires them.

When 1 million women have engaged in the campaign, EmpowHER will donate $50,000 toward women’s health research.

“Participants in this campaign are not required to spend a penny. Every time a new woman signs up to share a story, vote for a story, or share the campaign with others, money will be donated by EmpowHER to fund women’s health research,” said Thom Brodeur, Chief Marketing Officer for EmpowHER and campaign architect. “Our challenge to women is simple. Open your hearts, log onto the website, and pass it along. We’ll open our wallet and do the rest. We’re partnering with women to improve their health and change their lives, and we’re honored to play a role.”

The majority of campaign funds will be donated to HealthyWomen, the nation’s leading nonprofit health information source for women. For more than 20 years, HealthyWomen has been committed to improving women’s health through public education campaigns grounded in research among women nationwide.

“Studies show that when women share their health issues with other women, their state of mind improves, sometimes even having positive effects on their overall health,” said Jay K. Harness, MD, a member of EmpowHER’s Medical Advisory Board, President of Breast Surgery International and breast surgeon in Orange County, Calif. “For example, a recent report from the California HealthCare Foundation reported that when patients managing the same chronic condition share observations with each other, their collective wisdom can yield clinical insights well beyond the understanding of any single patient or physician.”

Dr. Harness, past president of the American Society of Breast Surgeons, goes on to say, “Studies have found that cancer patients who were isolated and lacked social interaction had greater tumor growth and worse prognosis. We firmly believe that loneliness and isolation can have a significant impact on a patient’s long-term battle with a disease.” Dr. Harness concluded that online communities are a great resource for patients to share and connect, but are not a substitution for oversight and guidance from a patient’s medical team.

“Women need to advocate for themselves and each other by calling for more gender-specific health research,” said Michelle King Robson, Founder, Chairperson and CEO of EmpowHER. “Much of the world’s health-related research remains male dominated, signaling there is still much to learn about women’s unique health conditions and the specific effects of procedures, drugs and diagnostics on women. This campaign was created to give women a voice in their own health, and to provide financial support to organizations dedicated to advancing women’s health research and advocacy.”

King Robson has witnessed this trend first-hand. Her site, launched just 24 months ago, reaches nearly 1.2 million unique visitors and viewers every month from women sharing their most intimate health conditions and then connecting with others for support. “I started this site after I experienced my own health nightmare and began telling my story. What has occurred has been a firestorm of other women who have found solace and better health by sharing on EmpowHER.com. We now want to take this to a new level of connectivity for all women around the globe by giving them a voice in their health through this campaign.”

To participate in the 1000Women Campaign, please visit www.1000Women.com.

About EmpowHER
EmpowHER is an award-winning health media company for women. The Company’s website provides visitors access to one of the largest women’s health and wellness content libraries on the web, as well as the largest online community of women discussing their health and wellness issues. EmpowHER promotes a “24 Hour Promise” to its visitors, who can come to the site, ask any health question and receive a response within 24 hours. Health care marketers rely on EmpowHER for reaching the most influential health and wellness buying audience on the Internet — women. Millions of women visit EmpowHER.com every year, making it one of the largest and fastest-growing resources dedicated exclusively to women’s health and wellness. For more, visit www.EmpowHER.com.

About HealthyWomen
HealthyWomen (HW) is the nation’s leading independent health information source for women. For more than 20 years, women have been coming to the HW for answers to their most pressing and personal health care questions. HW provides health information through a wide array of online content and print publications that are original, objective and reviewed and approved by medical experts. Its website, www.HealthyWomen.org®, was recognized by ForbesWoman as one of the “Top 100 Websites for Women” and was named the top women’s health website by Dr. Mehmet Oz in O, The Oprah Magazine and by Good Housekeeping magazine. To learn more, visit www.HealthyWomen.org.

id=”nav_links”>

CHICAGO, IL–(Marketwire – September 8, 2010) –  Graham Czach‘s wild creativity and unique versatile sound have earned the Windy City native a nomination for The Deli Chicago’s Artist of the Month. Fans can vote online through September 15 by clicking http://chicago.thedelimagazine.com/snacks.

The socially conscious rocker (www.grahamczach.com) is also teaming up with Planned Parenthood of Illinois (PPIL) to celebrate the official release of his independent debut album Lucid on Friday, October 15 at Martyrs (3855 North Lincoln Ave.) in Chicago. The show begins at 9:30 p.m. Tickets are $12 and may be purchased at www.martyrslive.com or at the door.

With a Chicago Music Award under his belt, the versatile singer/songwriter and multi-instrumentalist will bring his modern and progressive rock sensibilities to life performing with the album’s original band members: drummer Kris Myers (Umphrey’s McGee), keyboardist Matt Nelson (Lupe Fiasco, Matthew Santos), guitarist Chris Siebold (Howard Levy, Kick the Cat) and bassist Graham Burris (Lupe Fiasco, Matthew Santos).

Czach — whose album includes a powerful song about abortion rights titled “Choice” — is donating a portion of sales generated from the event to PPIL. PPIL’s 17 health centers throughout the state deliver comprehensive reproductive health care services, sex education, and sexual health information to more than 60,000 women, men, and teens each year.

In addition to Planned Parenthood of Illinois, a portion of the proceeds from Lucid is being donated to other non-profit organizations including Greenpeace, the American Cancer Society and the Art of Living Foundation.

As Lucid sheds light on these important social issues and more, Czach draws on a fascinating, diverse musical background — which includes his work with Chicago Afrobeat Project — to create musical landscapes as compelling as the lyrics. He was recently interviewed by Skope Magazine‘s editor Mike Friedman and by Lisa Smith of The Blend Magazine for their Take Action Party surrounding his earth-friendly messages.

Tapping into his childhood where Led Zeppelin, The Beatles and Crosby, Stills, Nash & Young were practically a religion, and later influences like Pink Floyd, Red Hot Chili Peppers, The Mars Volta and Jimi Hendrix, he infuses hard rocking, sometimes unusually metered grooves to four (and more) part vocal harmonies, beautiful acoustic melodies and vibrant unfolding string arrangements.

Click here to see all recent news from this company

MUNDELEIN, IL–(Marketwire – September 8, 2010) –  A little over a year after Medline Industries, Inc., the largest privately held manufacturer and distributor of healthcare supplies in the U.S., completed and opened its new environmentally conscious service facility center in Dubuque, Iowa, the building officially received Leadership in Energy and Environmental Design (LEED) silver certification.

LEED is an internationally recognized, third party validation system of certification for many buildings. It measures and evaluates design, construction, operation and maintenance solutions. LEED is generally viewed as a trusted benchmark for a building’s impact on the environment.

In order to receive this certification, Medline applied and the building was then evaluated by LEED, who allocated points based on preset green criteria — focusing on energy efficiency and CO₂ reduction. There are seven areas on which LEED evaluated the service facility: sustainability of the site, water efficiency, energy and atmosphere, materials and resources, indoor environmental quality, location and linkages, awareness and education, innovation in design and regional priority. To achieve silver certification, the second highest certification category, the service facility was awarded points that placed them in the 60-79 point range out of a 100-base point system. 

“The building was constructed with the environment and LEED certification in mind,” said Robert Abrams, the Corporate Director who oversaw the project. “Some of the green aspects of the 66,000-square-foot facility are daylight harvesting energy-efficient lighting, solar-tracking skylights, technologically advanced building insulation materials, tankless hot water heaters and a geothermal heating system.”

The installation of these and other green technologies resulted in an electrical use reduction of 320,565 kWh, which avoids more than 230 metric tons of carbon dioxide. This is equivalent to removing the CO₂ emissions from 26,131 gallons of gasoline consumed or 535 barrels of oil consumed. All of this gathered points for certification as well as small things, such as close parking for a Prius, cubical walls made with recycled fabric that traveled less than 500 miles from their manufacturer and energy efficient trash management. 

“I think it demonstrates Medline’s commitment to the environment as a company, and it was important for our customers,” Abrams said. “We’re being asked more and more what we’re doing to reduce our carbon footprint.”

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

BETHESDA, MD–(Marketwire – September 8, 2010) –  Coventry Health Care, Inc. (NYSE: CVH) announced today that John Stelben, Interim Chief Financial Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference in New York, New York, at 1:00 p.m. ET on Monday, September 13, 2010. 

The public may access a live webcast of the presentation on the Investor Relations page of Coventry’s website at www.coventryhealthcare.com. A replay of the presentation will be available at the same website following the presentation until Monday, September 20, 2010.

Coventry Health Care (www.coventryhealthcare.com) is a diversified national managed healthcare company based in Bethesda, Maryland, operating health plans, insurance companies, network rental and workers’ compensation services companies. Coventry provides a full range of risk and fee-based managed care products and services to a broad cross section of individuals, employer and government-funded groups, government agencies, and other insurance carriers and administrators.

RALEIGH, NC–(Marketwire – September 8, 2010) –  InoLife Technologies, Inc. (OTCBB: INOL), a service based healthcare products development, integration and marketing Company, is extremely pleased that their recently presented Cytochrome P450 2C1 test to determine a person’s ability to metabolize Plavix is immediately available to the medical industry which includes physicians, hospitals, medical clinics, and pharmacies. Physicians are currently placing orders on a daily basis and are incorporating the Cytochrome P450 2C1 Plavix Metabolizing test into their patients health programs. 

InoLife’s Cytochrome P450 2C1 test is currently being used to identify how a patient’s genetics may affect the body’s response to Plavix (Clopidogrel). The test is available through the medical community only including physicians, hospitals, and medical clinics. This test is not available for sale to the general public.

According to the FDA in a press release dated March 12^th, 2010 it is estimated that 2 percent to 14 percent of the U.S. population are poor metabolizers of certain medications. In 2009 the Federal Drug Administration approved wording on the drug label encouraging genetic testing for DNA variants based on specific risks. It is important to note that this drug metabolism test is not all-inclusive and is for the physician’s guidance only.

InoLife has incorporated the EasiCollect™ System, which combines an optimized foam collection surface with an FTA card for collection of buccal cells and preservation of DNA. InoLife prides itself in providing the EasiCollect™ System that adheres to the strict guidelines of the Clinical Laboratory Improvement Amendments (CLIA) that monitors approximately 200,000 laboratory entities. The Center for Medicare & Medicaid Services regulates all laboratory testing (except research) performed on humans in the U.S. through CLIA.

About InoLife Technologies, Inc.
InoLife is poised to become one of the premier U.S. marketers of state-of-the-art DNA-based test products. Positioned for growth and success in a burgeoning market, InoLife Technologies, www.inolifetech.com, is primarily focused on products, services and solutions that will enable state-of-the-art healthcare for today and the future for a diverse base of customers and end users. The Company’s mission is to identify, develop, integrate and bring to market innovative healthcare-based products and services that provide timely and practical solutions. The primary products and services that InoLife is currently addressing focuses upon those specific products and services that provide key solutions through the innovative use of specific DNA testing and Genetic analysis systems.

The principal customers of InoLife’s products and services are healthcare providers, physicians, practitioners, hospitals and outpatient facilities. InoLife will be marketing and distributing its products through traditional distribution channels. Additionally InoLife has developed certain products that can be sold directly to consumers and has created specific programs to reach those customers including e-commerce, direct sales, healthcare providers, pharmacies, distributors, retail sellers and specialty retailers.

(Plavix is a trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.)

Forward-Looking Statements
Safe Harbor Statement under the Private securities Litigation Reform Act of 1995: The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements including, but not limited to, certain delays beyond the Company’s control with respect to market acceptance of new technologies, products and services, delays in testing and evaluation of products and services, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission.

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Sept. 8, 2010) – ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF) (the “Company”) is pleased to announce that it has closed the private placement announced July 27^th, 2010. A total of 3,275,000 Units of the Company were issued at a price of $0.10 per Unit for gross proceeds of $327,500. All securities issued with respect to the private placement will be subject to a hold period expiring on January 8, 2011 in accordance with the policies of the TSX Venture Exchange and applicable Canadian securities laws. 

Each Unit consists of one common share of ALDA and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of ALDA at a price of $0.20 per common share for a period of two (2) years from the date of the issuance of the purchase warrant with a forced exercise provision attached to each warrant commencing on the day following the expiry of any applicable hold period on the underlying Common Share, stating that if, for ten consecutive trading days, the closing price of the listed shares of the Company exceeds $0.40 then the exercise period of the warrants will be reduced to a period of 10 days following such trading days. Net proceeds from the offering will be used for working capital.

The Company paid finders’ fees of $2,250 (5% of the gross proceeds of $45,000) to certain registrants with respect to the offering.

Insiders of ALDA subscribed for 677,500 Units on the same terms as arm’s length investors, constituting a related party transaction pursuant to Multilateral Instrument 61-101 and TSX Venture Exchange Policy 5.9. Such Insider participation was exempt from the requirement to obtain an independent valuation pursuant to Section 5.5(b) of MI 61-101 and the requirement to obtain minority shareholder approval pursuant to Section 5.7(1)(b) of MI 61-101.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T³6^® technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA
President & CEO
ALDA Pharmaceuticals Corp.
www.aldacorp.com

The Units, common shares, warrants and the common shares issuable upon exercise of the warrants have not been registered under the United States Securities Act of 1933 (the “Act”) and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as “outlook”, “will”, “could”, “would”, “might”, “remains”, “to be”, “plans”, “believes”, “may”, “expects”, “intends”, “anticipates”, “estimate”, “future”, “plan”, “positioned”, “potential”, “project”, “remain”, “scheduled”, “set to”, “subject to”, “upcoming”, and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

CINCINNATI, OH–(Marketwire – September 8, 2010) –  Compass Clinical Consulting features Jim Anderson, Chief Executive Officer of Cincinnati Children’s Hospital Medical Center (1996-2010), in a newly published, in-depth monograph on leadership excellence in healthcare.

LONG AGO AND FAR AWAY

In 1996, Cincinnati Children’s Hospital Medical Center (CCHMC) had 3,500 employees, 365,000 yearly patient encounters and $453 million in revenue. At the time, the hospital was looking for a new CEO to transform, grow and lead the organization into an uncertain future.

SAFE & OBVIOUS CHOICE

The safe and obvious selection would have been a candidate with extensive hospital administration training and long-term, proven leadership experience.

But, the CCHMC Board chose exactly the opposite.

A LAWYER … WITH A LEAN MANUFACTURING BACKGROUND?

They selected a lifelong attorney with a manufacturing executive background — a lawyer with an entrepreneurial bent and appreciation of lean manufacturing principles — James M. Anderson.

AND THAT MADE ALL THE DIFFERENCE

In all measures, the hospital’s success and growth under Jim Anderson’s visionary leadership was extraordinary. When he retired at the end of 2009, CCHMC had grown to over 11,000 employees, 925,000 yearly patient encounters and $1.6 billion in revenue. Under Mr. Anderson’s leadership CCHMC was transformed from a small regional hospital serving the greater Cincinnati area into an internationally recognized leader in improving healthcare outcomes, experience and results for children.

HOW DID IT HAPPEN?

To learn more, read the newly published Compass Clinical Consulting “Profiles in Healthcare Leadership” monograph, featuring hard-won lessons from Jim Anderson’s career at CCHMC.

Key Lessons for Hospital Leaders:

• How setting a goal at zero defects changes your aspirational framework and exemplifies the extraordinary commitment required of patient- and family-centered care
• What to do when your best people tell you it can’t be done — and how to do it anyway, saving lives
• Lead with lawyers to reduce hospital, healthcare and legal costs
• How to build an Entrepreneurial Healthcare Organization
• One simple message to align the workforce and leadership

Compass Clinical Consulting’s “Profiles in Healthcare Leadership” are the products of interviews with transformational leaders in today’s healthcare industry — all of whom have demonstrated courage, ingenuity and the hard work needed to create dramatic, measurable and sustainable improvements in healthcare. These featured leaders challenge assumptions, see things differently and create remarkable breakthroughs.

DOWNLOAD your copy of Profiles in Healthcare Leadership: An Interview with Jim Anderson

About:
Compass Clinical is a healthcare consultancy founded in 1979 and based in Cincinnati, OH. Compass experts have helped hundreds of hospitals and health systems prepare for accreditation, optimize labor cost management, manage clinical resources, and improve patient throughput and physician relations. Compass also places interim healthcare executives.

DENVER, CO–(Marketwire – September 7, 2010) –  Eating Recovery Center (www.EatingRecoveryCenter.com) today announced that two of the nation’s foremost eating disorders experts have joined its executive team. Craig Johnson, PhD, FAED, CEDS, has been named chief clinical officer of Eating Recovery Center and Ovidio Bermudez, MD, FAAP, FSAM, FAED, CEDS, will become the medical director of Eating Recovery Center’s new child and adolescent treatment program. The appointments of these renowned doctors, known for their scholarship, dedication and clinical expertise, further elevate Denver, Colo., as the nation’s hub for eating disorders treatment.

Eating Recovery Center, a national center for eating disorders recovery providing comprehensive treatment for anorexia and bulimia, currently operates a licensed behavioral hospital for adults with serious eating disorders and an outpatient office, both located in Denver, Colo.

“Eating disorders impact 11 million Americans and remain the deadliest mental illnesses,” said Kenneth L. Weiner, MD, CEDS, founding partner and chief executive officer of Eating Recovery Center. “With the addition of Drs. Johnson and Bermudez, Eating Recovery Center has assembled an internationally renowned team to help patients tackle every level of care from critical inpatient care to outpatient treatment.”

As chief clinical officer, Dr. Johnson will direct Eating Recovery Center’s clinical program development and implementation. He will also drive the Center’s research efforts in conjunction with Emmett R. Bishop, Jr., MD, CEDS, founding partner and medical director of adult services of Eating Recovery Center. A leader in the field of eating disorders treatment since 1979, Dr. Johnson founded and was most recently the director of the Eating Disorders Program at Laureate Psychiatric Hospital in Tulsa, Okla. He is a professor of psychiatry at the University of Oklahoma Medical School and has formerly held faculty appointments at the University of Chicago and Northwestern University Medical Schools. 

Dr. Johnson was the founding editor of the International Journal of Eating Disorders, as well as a founding member of both the Academy of Eating Disorders and the Eating Disorders Research Society. He is also past president of the National Eating Disorders Association. He has authored three books, more than 70 scientific articles, and has been the recipient of several distinguished contribution awards.

“Eating Recovery Center’s ability to quickly adapt treatment innovations has led to the organization becoming a leader in the field of eating disorders. I look forward to working with this distinguished group to further advance the field,” said Dr. Johnson.

Dr. Bermudez, nationally and internationally recognized as an expert in the treatment of adolescents with eating disorders, will apply his expertise to the development of Eating Recovery Center’s new child and adolescent treatment program. Most recently the medical director of Laureate’s Eating Disorders Program, Dr. Bermudez is co-founder of the Eating Disorders Coalition of Tennessee (EDCT), vice-president and co-founder of the Oklahoma Eating Disorders Association (OEDA), as well as past president of the National Eating Disorders Association. He also serves in several leadership positions within the Academy for Eating Disorders.

Dr. Bermudez holds an academic appointment as clinical professor of psychiatry and pediatrics at the University of Oklahoma College of Medicine. He was previously faculty at the Vanderbilt University School of Medicine. Additionally, he is a Certified Eating Disorder Specialist and member of the International Association of Eating Disorders Professionals. Dr. Bermudez has lectured nationally and internationally on eating disorders, childhood obesity and other topics related to adolescent healthcare. He has been widely recognized for his dedication and advocacy on behalf of sufferers and families.

“I am thrilled to join the clinical team at Eating Recovery Center to develop an innovative program focused on the specialized needs of children and adolescents with eating disorders,” said Dr. Bermudez. “Our approach will be sensitive to the developmental needs of each patient and address the medical, behavioral and psycho-social aspects of their eating disorder while working closely with each family — all important components of successful treatment and lasting recovery.”

Denver, Colo., now offers individuals with eating disorders a full spectrum of care overseen by the nation’s leading eating disorders clinicians. Drs. Johnson and Bermudez join Eating Recovery Center founders, Drs. Weiner and Bishop, recognized experts with more than 50 years combined expertise, in providing inpatient, residential, partial hospitalization, intensive outpatient and outpatient services at Eating Recovery Center’s facilities. A partnership with Denver Health’s A.C.U.T.E. eating disorders program, directed by Philip Mehler, MD, CEDS, an expert in the medical complications of eating disorders, enables Eating Recovery Center to collaboratively provide care for severely medically compromised eating disorders patients.

About Eating Recovery Center
Eating Recovery Center is a national center for eating disorders recovery providing comprehensive treatment for anorexia and bulimia. Denver-based facilities include a licensed behavioral hospital treating adults, an outpatient office and a facility treating children and adolescents scheduled to open in November 2010. Under the personal guidance and care of Drs. Weiner and Bishop, and the newest additions to our leadership team — Drs. Craig Johnson and Ovidio Bermudez, our collaborative programs provide a full spectrum of services for children, adolescents and adults. Our integrated program offers patients from across the country a continuum of care that includes inpatient, residential, partial hospitalization, intensive outpatient and outpatient services. Our compassionate team of professionals collaborates with treating professionals and loved ones to cultivate lasting behavioral change. For more information please contact us at 877-218-1344 or [email protected] or confidentially chat live on our website at www.EatingRecoveryCenter.com.

Click here to see all recent news from this company

UTICA, NY–(Marketwire – September 7, 2010) –  CONMED Corporation (NASDAQ: CNMD), a medical technology company specializing in medical devices for surgical and patient monitoring markets, announced today that the Company will participate in three investor conferences during the second week of September 2010 as follows:

• Morgan Stanley Global Healthcare Conference on September 14, 2010 at 3:20 PM Eastern, in New York City

• CL King Best Ideas Conference on September 15, 2010 at 2:45 PM Eastern, in New York City

• Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 at 2:40 PM Eastern, in Boston

Mr. Joseph J. Corasanti, President and CEO of CONMED, will discuss the Company’s business. The live webcasts of CONMED’s presentations will be available at www.conmed.com in the Investor Relations – Events Calendar section of the website and will be available for replay through September 24, 2010.

CONMED Profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and patient monitoring. The Company’s products serve the clinical areas of sports medicine-arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. Surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology use the Company’s medical devices. Headquartered in Utica, New York, the Company’s 3,300 employees distribute its products worldwide from several manufacturing locations.

Forward Looking Information

Certain statements made in the presentations may constitute forward-looking statements. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. They will be based upon management’s expectations and involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements therein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to: (i) the failure of any one or more of management’s assumptions to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and Quarterly Reports on Form 10-Q; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition (and its integration) or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw material, transportation, or litigation; and/or (viii) the Company’s ability to devise and execute strategies to respond to market conditions.

TAMPA, FL–(Marketwire – September 7, 2010) – Sage North America Healthcare Division, which provides electronic health records (EHR) and practice management software and services to approximately 80,000 physicians in North America, today announced that Mayo Regional Hospital, based in Dover-Foxcroft, ME, has selected Sage Intergy EHR for the hospital’s medical practices. 

The 25-bed critical access non-profit hospital owns and operates eight physician practices. Mayo Regional Hospital selected Sage Intergy EHR following a two-year evaluation process of EHR systems in the marketplace. Sage Intergy could easily handle the hospital’s billing requirements, along with the system’s robust practice management needs, said Ben Dever, Director of Mayo Practices Associates for the Mayo Regional Hospital.

“The uniqueness of our billing system and its complexities placed Sage Intergy at the top of our vendor list,” said Dever. “In our search for an EHR, we needed a system that could handle a robust, multi-practice billing system while providing clear reporting metrics and outcomes. Intergy proved the most capable system to meet our needs.”

Sage Intergy EHR is a comprehensive clinical, financial and administrative solution that empowers physicians to advance the quality and efficiency of care they deliver. The Sage Intergy family of products includes integrated practice management, electronic health records, clinical and business intelligence and tools for online patient engagement. Providers can access Sage Intergy from multiple practice locations, from home, or other remote locations either through a central patient database server, or as a Sage-hosted solution on a monthly subscription basis. 

Sage Intergy EHR easily tracks the details of a patient’s clinical history, shares and manages clinical information and combines complex medical practice functions into easy-to-navigate menus. Sage Intergy EHR features centralized financial operations including billing, reporting, task management, and fully integrates with EDI services, Sage Intergy Practice Portal, Sage Intergy RIS and Sage Practice Analytics.

Dever said Mayo Regional Hospital is working to attain meaningful use, as driven by the federal government’s recent passing of a healthcare stimulus package. Sage Intergy EHR will provide the hospital’s practices with reporting and data collection capabilities as required by the meaningful use rules.

The clinics of Mayo Regional Hospital see more than 50,000 patients a year, and, while cost containment of moving from a paper to electronic system appealed to the hospital’s selection committee, adding Sage Intergy EHR to its healthcare system is driven by providing better quality of care, and tracking outcomes to improve treatment and care options for patients, Dever said.

“We’ll now be more easily able to track patients’ progress through their electronic records, and share patient data between the hospital and its clinics,” said Dever. “This will lead to quicker delivery of care and better, higher quality, encounters with our patients.”

Sage has been providing ambulatory healthcare systems for nearly 30 years, providing practice management solutions, electronic health records and other services to streamline patient care, as well as is a leading supplier of business management software and services, serving more than 6.2 million small and midsized business customers worldwide. 

View Sage Healthcare Division YouTube interviews.
View Sage Healthcare Division information.

About Mayo Regional Hospital
Mayo Regional Hospital is a non-profit, 25-bed critical access hospital located in Dover-Foxcroft, the county seat of Piscataquis County. Mayo Regional opened in 1978 and is governed by Hospital Administrative District 4, which was established by 12 towns to serve the healthcare needs of residents in a three-county area of rural central Maine. Mayo Hospital has 22 physicians and 375 staff members dedicated to providing acute medical/surgical care, intensive care, surgical services and obstetrics in an inpatient setting, as well as a wide array of outpatient services. Mayo Practice Associates, a department of the hospital, owns and operates eight physician practices in Corinna, Dexter, Dover-Foxcroft, Guilford and Milo.

About Sage North America
 Sage North America is part of The Sage Group plc, a leading global supplier of business management software and services. Sage North America employs 4,000 people and supports 3.1 million small and midsized business customers including approximately 80,000 physicians. The Sage Group plc, formed in 1981, was floated on the London Stock Exchange in 1989 and now employs 13,100 people and supports 6.2 million customers worldwide. For more information, please visit the website at www.sagenorthamerica.com.

© 2010 Sage Software, Inc. All rights reserved. Sage, Sage Software, Sage logos and the Sage product and service names mentioned herein are registered trademarks or trademarks of Sage Software, Inc. or its affiliated entities. All other trademarks are the property of their respective owners.

BOCA RATON, FL–(Marketwire – September 7, 2010) –  Banyan Corporation (PINKSHEETS: BNYN) announced that it has reached an agreement with Mark Eric Bailey to partner with it in the development of its America’s Dentist concept. When operational, America’s Dentist will offer a vast array of services to dental practices nationwide, including marketing; real estate/leasing support; practice management and analysis; finance; branding; practice purchase and sale representation and practice transitions.

Mark Eric Bailey has served general & specialty dentists nationwide regarding practice finance & advice at Capital4HealthCare, LLC. In 2005, he founded Dentcetera Dental Practice Advisors, LLC which provides advice, analysis and buyers representation for general & specialty dentists and in 2007 he co-founded edentalspace.com, the first global social networking site exclusively for dental professionals. Mr. Bailey has completed 463 dental practice transitions in his career. Dentcetera services will be rebranded Americas Dentist and will feature buyer’s representation or traditional practice brokerage services.

Mr. Bailey stated, “I am excited by this opportunity to participate with Banyan Corporation in the development of America’s Dentist. In today’s economy, it is more important than ever before for a dental practice to operate at its optimum, not just clinically but as a business. At America’s Dentist we will feature state-of-the-art practice management software to analyze the present business performance of a practice, and our consulting team will be able to quickly assess and recommend decisions to immediately increase a practice’s performance. Whether our services lead to the dentist’s long-term improved practice performance or help the dentist enhance practice performance in preparation for merger or acquisition, America’s Dentist services will be invaluable.”

The multi-billion dollar dental industry is the most organized of healthcare professions. Banyan Corporation believes it can leverage of the significant experience of both Mr. Bailey and its past ventures to move successfully into the dental arena.

About Banyan Corporation:

Banyan Corporation is a publicly traded holding company focused on investing in and building a network of operating subsidiaries engaged in various innovative businesses. Currently the company’s subsidiaries, Premier Medical Group, Inc. and affiliated companies, provide diagnostic testing services to physicians nationwide.

This Press Release contains or incorporates by reference forward looking statements including certain information with respect to plans and strategies of Banyan Corporation. For this purpose, any statements contained herein or incorporated herein by references that are not statements of historical fact may be deemed forward looking statements. Without limiting the foregoing, the words “believes,” “suggests,” “anticipates,” “plans,” “expects,” and similar expressions are intended to identify forward looking statements. There are a number of events or actual results of Banyan Corporation operations that could differ materially from those indicated by such forward looking statements.

SCHAUMBURG, IL–(Marketwire – September 7, 2010) –  Network Services Company, an international organization of health care and janitorial supply distributors, recently announced the launch of Healthy Measures^™, a three-step consulting program to aid hospitals in the prevention of health care acquired infections (HAIs) while increasing patient satisfaction scores.

Partnering with health care facilities to assess their current conditions and cleaning practices, Healthy Measures (www.HealthyMeasuresOnline.com) is helping hospitals meet the standards and guidelines for housekeeping and hand hygiene recommended by the Centers for Disease Control and Prevention’s (CDC) Healthcare Infection Control Practices Advisory Committee (HICPAC).

“Infections pose an extreme risk to patients during a hospital stay, especially if the patient is already in a vulnerable condition,” said Kevin Rudd, Network Services’ chief marketing officer. “We’ve designed Healthy Measures to be an industry-leading solution that enables hospitals to reduce infection rates, thereby safeguarding patients and improving overall patient satisfaction.”

The CDC estimates there are approximately 100,000 deaths suffered annually in the U.S. stemming from an estimated two million preventable HAIs. Some of the pathogens that result in HAIs, which have been found to be readily transmitted from environmental surfaces to health care workers’ hands and to patients, include C. difficile (Clostridium difficile), methicillin-resistant S. aureus (MRSA), acinetobacter, norovirus and vancomycin-resistant enterococcus (VRE). But implementation of a hand hygiene and surface sanitation program like Healthy Measures can result in dramatically lower rates of infection.

The Healthy Measures program is a three-step process comprised of:

• Interviews with key personnel to gain an understanding of the facility’s current culture and challenges related to infection prevention;
• Facility assessment focusing on patient, public and staff areas to gain an understanding of current processes and procedures, and products used;
• Implementation of a comprehensive and customized joint-action plan related to hand hygiene and surface sanitation.

“The Healthy Measures Program provides a second pair of eyes when evaluating a facility and emphasizes collaboration by working closely with hospital staff to arrive at a solution,” said Rudd. “As part of the comprehensive solution, we provide checklists, educational and training materials, customizable signage, monthly tips, association guidelines, hospital rating websites and access to extensive research.”

Research indicates HAIs have become a financial risk to both individual health care facilities and the nation’s health care industry. The average cost of one HAI to a hospital is $14,000, while the average cost to the U.S. health care industry is between $4.5 and $5.7 billion annually (Source: Stone, et al. American Journal of Infection Control 2002; 30:145-52).

“Disinfection of the hospital environment and patient care equipment are essential strategies to prevent the spread of HAIs,” said Blake Kite, director of environmental services at Banner Estrella Medical Center. “One of the biggest things that impressed me about Healthy Measures was that we could decide upon our own action plan. We felt included in the process and part of the solution.”

About Network Services Company
Schaumburg, Ill.-based Network Services Company is a member-owned distribution network of more than 75 member-distributors with combined annual revenue of more than $12 billion. Members include distributors of janitorial supplies and equipment, as well as foodservice disposables and industrial packaging supplies and equipment. For more information about Network Services, please visit www.nsconline.com.

Click here to see all recent news from this company

WESTLAKE VILLAGE, CA–(Marketwire – September 7, 2010) – Compulink Business Systems, Inc., the industry leader in fully customizable electronic health records (EHR) and practice management solutions, announced today it is providing an unrestricted educational grant to the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO®) to develop online courses on EHR for ophthalmic medical personnel.

The online course series allows users to train at their convenience and pace with e-learning technology that transcends the traditional classroom environment and demonstrate their EHR knowledge and performance to qualify for certification. The course is open to two key groups of ophthalmic caregivers: ophthalmologists and ophthalmic allied health personnel, who assist the ophthalmologist in aspects of patient care. In addition, with the comprehensive online course content proposed, the e-learning will be of great interest to the entire eye care team: clinic managers, front office personnel, ophthalmic photographers, ophthalmic nurses, and other members of the eye care team.

“With this significant grant to JCAHPO, Compulink demonstrates its commitment to the ophthalmic community through actions as well as words,” said Link Wilson, President and CEO, Compulink. “We believe it’s critical to help all members of the eye care team learn how to implement, customize and utilize EHR solutions, understand meaningful use and, ultimately, deliver better patient care through the widespread adoption of electronic records.”

The training modules, which are broken into (1) education and training and (2) testing components, encompass the following content categories:

• Electronic Health Records
• Patient Management and Scheduling
• Insurance and Billing
• Financial Management
• Ambulatory Surgical Center
• Systems

Module content also includes such topics as: chart documentation and coding; history and examination; e-Prescribing; disease management; lab orders and results reporting; PQRI data verification; images; patient scheduling and contact management; insurance claims; Medicare; billing and coding; scribing; financial reports; ASCs; and security.

The Compulink grant supports training content and multimedia development, psychometric services for valid assessment, CME and CE applications, pilot testing and project administration expenses.

“EHR is a very important area for training the eye care team in today’s health care environment,” stated William Ehlers, MD, JCAHPO President. “With the government requirements and incentives for transitioning to EHR, it is imperative that all members of the eye care team build their EHR competencies.” 

The JCAHPO is a non-profit organization dedicated to the quality and availability of ophthalmic patient care by promoting the value of qualified allied health personnel and by providing certification and education. 

The program is expected to launch at the American Academy of Ophthalmology (AAO) in Chicago, October 16-19, and will be administered at www.actioned.org, the online training site of the JCAHPO.

About Compulink
With more than 15 years experience in EHR implementation planning, management and technology, Compulink’s fully customizable CCHIT Certified EHR features clinical documentation, exam templates, fully integrated e-Prescribing, and PQRI automation. Backed by an exclusive EHR Success Guarantee and ARRA Certification Guarantee, Compulink also offers unparalleled financing options with its two-year deferred payment plan. For more information, contact Compulink at: [email protected] or 800.456.4522, or visit us at www.compulinkadvantage.com.

About JCAHPO
The Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO®) was established as a not-for-profit organization in 1969 to offer certification and continuing education opportunities to ophthalmic allied health personnel. Since then, more than 25,000 people in the U.S., Canada, and around the world have earned JCAHPO certification. For more information, visit: http://www.jcahpo.org/.

Click here to see all recent news from this company

REDWOOD CITY, CA–(Marketwire – September 7, 2010) – Lunera Lighting, Inc., a Silicon Valley company that designs, manufactures, and markets next-generation LED lighting, is pleased to announce that its award winning, energy efficient LED fixtures are now available for purchase on the General Services Administration (GSA) Schedule. New to the Lunera® team, Harpreet Walia, head of Government Affairs, will be leading the company’s government sales efforts.

The GSA Schedule program provides access to over 11 million commercial products and services at volume discount pricing. To qualify for the GSA Schedule program, all approved vendor products must be compliant with the commercial environment intended.

“We believe in creating sustainable, high quality, digital lighting through a combination of innovative fixture design and state-of-the-art technology. We are delighted that our products were approved on the first round to be included on the GSA schedule. Our commercial LED lighting products enable government agencies to progress towards energy efficient lighting for improved building performance and a more productive work environment,” stated Michael Lesyna, CEO of Lunera Lighting.

Advantages of purchases made through the GSA Schedule:

• Administrative work reduction
• Reduced purchase cycle
• Ease of use
• Procurement control

Lunera products can be purchased and ordered directly by federal customers through the GSA Advantage!® online shopping and ordering system. Products can also be purchased and ordered through Lunera directly. Lunera’s inclusion on the GSA Schedule is enabled through an agreement with Fedlight Supply and can be found through schedule number GS07F-7118B on SIN:206-4.

Lunera’s energy efficient LED fixtures are compliant with the Buy American provisions (Section 1605) of the American Reconstruction and Reinvestment Act of 2009 (ARRA) and the Buy American Act. Lunera’s fixtures are produced and assembled in California and are designed for ARRA-funded public works projects that advance energy efficiency in new construction and building retrofits.

The company is committed to creating products that produce high quality light, following sustainable green building practices, and striving for the greatest level of customer satisfaction. Lunera fixtures help buildings acquire LEED certification, while providing quantifiable energy and maintenance savings leading to a strong return on investment in LED lighting.

Promises Kept vs. Promises Made
The lighting industry is undergoing a disruptive change in technology for the first time in over 100 years. Analysts predict that LED lighting will become the predominant light source within a few years.

Commercial building owners are open to change based on the promise of digital LED technologys: dramatic energy and maintenance savings; reduced environmental impact; and on Lunera’s promise of delivering these benefits while improving the quality of light and fixture design to enhance the space for a building’s occupants. Obtaining accurate information about LED lighting is key to making an educated product choice.

Lunera is committed to providing comprehensive information on LED technology, its environmental benefits plus maintenance and energy savings to help potential customers make an informed purchase decision. Corporate customers interested in making the switch to commercial LED lighting should visit Lunera’s website for more information.

About Lunera Lighting
Lunera Lighting is an award-winning technology innovator leading the transformation from analog to energy-efficient LED lighting. Manufactured in the USA, Lunera’s premium lighting fixtures are particularly attractive when seeking LEED certification, since LED lighting substantially impacts LEED points in “green” buildings. The company is also a firm believer in social and environmental responsibility and has made it part of their corporate philosophy. Visit http://www.lunera.com for more information or contact Lunera at 650-241-3875 or by email at [email protected].

Click here to see all recent news from this company

BETHESDA, MD–(Marketwire – September 3, 2010) – GetWellNetwork, Inc. today introduced a new pediatric Asthma Care Plan for children’s hospitals, available now through GetWell Town™. The Asthma Care Plan helps improve patient outcomes by engaging patients and their families by teaching them to successfully manage the disease at home, leading to fewer hospital stays and emergency department visits. The GetWell Town Asthma Care Plan is immediately available. 

Pediatric asthma is the most common chronic condition among children under 18, affecting more than 6 million children according to the American Lung Association. It has costly effects for both parents and children, costing nearly $719 million in parents’ loss of productivity and asthma related school absences⁽¹⁾. At the same time, it is a condition that can be managed successfully with proper education and care plan. 

“We are truly excited about launching the GetWell Town Asthma Care Plan. The Asthma Care Plan enables care providers to easily involve children and families in a comprehensive educational program that will be instrumental in preparing them to effectively manage their condition at home,” said Sandra Marken, director of nursing pediatrics, Cardon Children’s Medical Center. “We believe that actively engaging children and families in this care plan will result in a decrease of readmissions within 30 days post discharge.”

The new GetWell Town Asthma Care Plan engages parents and children starting at day of admission. It leverages award-winning asthma education videos from KidsHealth^® to educate patients on key concepts that prepare them for managing their condition at home. The Asthma Care Plan introduces information about the disease in four phases:

• Phase One: Patients are introduced to the basics of asthma and begin their in-patient education curriculum.
• Phase Two: Children learn about medications and tools that help manage their condition, and the common triggers to avoid such as second-hand smoke.
• Phase Three: Patients and families are instructed on how to create a safe home environment and taught self-monitoring techniques to recognize signs and symptoms of potential flare-ups; their Care Team also checks-in to monitor their progress through the Asthma Care Plan.
• Phase Four: Patients learn about the take-home Asthma Management Plan and the importance of completing a plan of action before discharge. Patients and family members can also repeat any of the four phases and contact staff members for assistance throughout the learning process.

“The interactive Asthma Care Plan truly allows hospital staff to incorporate condition-specific education throughout the entire care process. By allowing patients and families to progress through the educational plan on their own, they are likely to receive important information at the right time in their hospital stay to better understand their condition and how to manage it,” said Dr. Neil Izenberg, founder and editor-in-chief of KidsHealth. “We are excited that the comprehensiveness of the KidsHealth Asthma Care Suite fits so well into the GetWell Town Asthma Care Plan to create a standardized care plan for young asthma patients.”

“We are honored to work with our GetWellNetwork Children’s Hospital partners and KidsHealth to proactively engage patients and families in managing this condition post hospitalization,” said Shannon O’Neil, director, pediatric product line, GetWellNetwork, Inc. “Further we are confident that young patients who successfully complete the GetWell Town Asthma Care Plan will be better prepared to enjoy active participation in home and school activities.”

About KidsHealth^®

KidsHealth creates engaging online, print, and video media about a wide range of health and family issues in English and Spanish. KidsHealth licenses online content, which can be private-labeled and displayed on a licensee’s website. KidsHealth has a physician-directed, professional editorial staff — and is the largest resource of online children’s health, behavioral, and developmental information written for three distinct audiences: parents, kids, and teens. KidsHealth also creates KidsHealth in the Classroom, a free website for educators featuring standards-based health curricula, activities, handouts, and more. KidsHealth is part of Nemours, one of the nation’s largest nonprofit pediatric health systems. For more information about KidsHealth, please visit www.kidshealth.org/mktg/intro/.

About GetWell Town
GetWell Town was developed in collaboration with GetWellNetwork’s National Children’s Hospital Task Force, comprised of 15 pediatric facilities across the U.S. as well as direct input from pediatric patients and their families. GetWell Town is designed to complement the kid-friendly spaces that children’s hospitals have worked hard to create and features exclusive content in partnership with KidsHealth®, part of The Nemours Foundation’s Center for Children’s Health Media.

About GetWellNetwork
GetWellNetwork, Inc. uses the bedside TV to entertain, educate and empower hospital patients and caregivers to be more actively engaged in their care. This patient-centered approach improves both satisfaction and outcomes for patients and hospitals. GetWellNetwork is the leader in interactive patient care solutions and exclusively endorsed by the American Hospital Association. More information about GetWellNetwork can be found at www.GetWellNetwork.com.

(1) Wang LY, Zhong Y, Wheeler L. “Direct and Indirect Costs of Asthma in School-Age Children.” Preventing Chronic Disease, 2(1): [serial online], January 2005.

Click here to see all recent news from this company

MIAMI, FL–(Marketwire – September 3, 2010) –  Simulated Environment Concepts, Inc. (PINKSHEETS: SMEV), makers of the high pressurized dry water massage and wellness equipment, SpaCapsule, announced today that hot on the heels of the twelve capsule deal with UK-based Aspire Consulting, the SpaCapsule has once again made a splash in international press, courtesy of Ireland’s Life and Fitness Magazine.

Dr. Ella Frenkel, CEO and President of Simulated Environment Concepts, Inc. (SE Concepts), said, “Publicity comes naturally to us. Because of the innovation of our Spa Capsule, we have been featured in numerous TV and print venues — ABC’s Good Morning America, CBS’s Doctors Show, NBC’s Today Show, Rob Report and the New York Times, to name a few. However, it is always a great feeling when you see an unsolicited article about us; especially in a prominent magazine such as Life and Fitness Magazine Ireland.”

Freely distributed nationwide to selected gyms and leisure centers, Life and Fitness Magazine Ireland is one of the country’s leading Health & Fitness Publications covering such topics as weight loss, health, nutrition, wellness, sport and travel.

The featured article, “The Spa Capsule Has Arrived In Ireland” (September 1, 2010), continues to demonstrate the significance of the SpaCapsule and its place in not just the therapeutic markets, but in health and fitness overall. Named “the ultimate wellbeing experience” by Life and Fitness Magazine Ireland, the article continued on to state, “this is an excellent opportunity for those in the wellbeing, massage and sport therapy fields to add to their client offering.”

With distribution deals like that of Aspire Consulting for Vibralife and Zen & O for Lady Fitness, SE Concepts intends to carry on with its expansion into the health and wellness markets, while continuing to cultivate corporate, leisure and therapeutic markets worldwide.

About Simulated Environment Concepts, Inc.

Simulated Environment Concepts, Inc. is the developer of a variety of products for wellness, relaxation, weight loss, and rehabilitation. Our aqua massage and hydromassage products are used by Doctors, Gyms, Spas, retail locations, offices, residential and many other venues. Incorporating oxygen, aromatherapy, massage, and even music or video from an iPod or an iPhone, our products deliver consistent results and excellent earning potential for businesses. For more information on Simulated Environment Concepts and its flagship product, SpaCapsule®, PTjetCapsule™, and Celude Laboratories™ products you can visit the company’s product website at www.spacapsule.com, the corporate website at www.seccorporation.com, or request more information via email at [email protected], or call at (888) 757-0797 or (305) 651-9200.

Safe Harbor

Statements in this news release that are not historical facts, including statements about plans and expectations regarding products and opportunities, demand and acceptance of new or existing products, capital resources and future financial results are forward-looking. Forward-looking statements involve risks and uncertainties which may cause the Company’s actual results in future periods to differ materially from those expressed. These uncertainties and risks include changing consumer preferences, lack of success of new products, loss of the Company’s customers, competition and other factors discussed from time to time in the Company’s filings with the Securities and Exchange Commission.

SpaCapsule is registered trademark of Simulated Environment Concepts, Inc.

Click here to see all recent news from this company

AUSTIN, TX–(Marketwire – September 3, 2010) –  American Physicians Service Group, Inc. (“APS”) (NASDAQ: AMPH) today announced that its Board of Directors had authorized the early redemption of all of APS’ 3% Series A redeemable preferred stock, valued at approximately $6 million, and payment of accrued dividends on the preferred stock through the redemption date.

Mr. Ken Shifrin, Chairman of the Board, said, “This stock was issued in 2007 in payment of refundable surplus deposits provided by our insured doctors three decades ago when our forerunner, American Physicians Insurance Exchange (“APIE”), came into existence. It is very gratifying to satisfy this obligation to those early pioneers who were believers in the doctor-owned insurance concept.”

These distributions will be made on September 24, 2010 to shareholders of record on September 3, 2010.

APS is an insurance services firm with subsidiaries and affiliates which provide medical malpractice insurance and related services for physicians and other healthcare providers. APS is headquartered in Austin, Texas.

This press release includes forward-looking statements related to APS that involve risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are made in reliance on the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. For further information about these factors that could affect the future results of APS, please see the recent filings with the Securities and Exchange Commission. Prospective investors are cautioned that forward-looking statements are not guarantees of future performance. Actual results may differ materially from management expectations. Copies of the filings are available upon request to APS.

OAK BROOK, IL–(Marketwire – September 2, 2010) –  Virtual Pharma Rep™, a leader in e-detailing marketing strategies, announced today that the company has entered into an agreement to provide their patent-pending e-detailing platform for use as the foundation for a new progressive communication program, in partnership with digitalDVM™, a sales and marketing solutions provider for the animal health industry.

Virtual Pharma Rep™ facilitates a paradigm shift in the traditional sales process, and revolutionizes expensive sales models with a fresh, value-added approach that supplements existing field reps and provides a new voice in the sales process. The partnership between Virtual Pharma Rep™ and digitalDVM™ brings together key components that supplement and enhance existing sales and marketing strategies for the animal health industry. Timely, relevant product and support information will be provided to busy veterinarians in an appealing format that meets the needs of the growing number of practices who prefer online resources that can be accessed at their convenience. 

“Virtual Pharma Rep™ has had significant success in the pharmaceutical industry,” said Jim Rediehs, CEO of Virtual Pharma Rep™. “The versatility of our e-detailing platform allows us to branch into new markets like Animal Health. It shares many similarities with the pharmaceutical market, and VPR provides a tool we know will prove useful for sales reps and veterinarians to maximize time, enhance education and therefore better serve their clients within the animal health industry.”

“More than 80% of physicians participate in e-detailing from pharmaceutical companies, and with the explosive growth of internet use among veterinary professionals, now is the time to make this service available to those in the animal health industry,” said Daryl Schraad, president of digitalDVM™. “virtualVetRep™ complements existing sales and marketing efforts by adding increased voice to top veterinary targets, and provides a cost-effective alternative to increasing field representatives in remote geographical regions.”

digitalDVM™’s virtualVetRep™ offers customized one-on-one virtual sales calls that include streaming video messages, live chat and sample or literature requests. In addition, the service connects veterinarians directly with their field sales representative, which helps optimize field sales call cycles and clinic staff’s time.

The virtualVetRep™ service is available to animal health product manufacturers and distributors worldwide.

About Virtual Pharma Rep™

Virtual Pharma Rep™ is revolutionizing the pharmaceutical industry by leading the paradigm shift to virtual sales support and service models that enhance or replace existing and expensive pharmaceutical marketing strategies. Led by a team that is highly experienced in the creation of future sales and growth strategies in pharmaceuticals, Virtual Pharma Rep™‘s patent pending sales platform shares a cost reduction within the pharmaceutical industry by streamlining existing sales and marketing strategies. In addition, thanks to VPR’s disease awareness, management and compliance processes, VPR assists with overall long-term healthcare cost reductions in the form of fewer doctor’s office visits and hospitalizations. For more information please visit www.virtualpharmarep.com.

About digitalDVM™
With a growing portfolio of advanced technology and innovative marketing platforms, digitalDVM™ enables animal health companies to gain more effective, immediate access to progressive veterinarians. Best-in-class capabilities include virtualVetRep™, an exclusive e-detailing platform for product and service information, groupDVM™ ecommerce solutions, and virtualRepCoach™, the digital alternative for sales representative training and development. Based in Denver with a worldwide clientele, the company works directly with product manufacturers and distributors throughout the animal health industry. More information is available at www.digitaldvm.com.

NEW YORK, NY–(Marketwire – September 2, 2010) –  MedLink (OTCBB: MLKNA), a leading provider of Electronic Health Records and practice management solutions, today announced a partnership with Thrasys, Inc. a provider of next-generation health information technology and solutions. MedLink and Thrasys have collaborated to provide interoperability and health record management based on SyntraNet from Thrasys, a cloud based Health Information Exchange (HIE) and Collaboration Network. SyntraNet enables more efficient and coordinated care across healthcare communities.

“The Agreement with Thrasys strengthens MedLink’s ongoing RHIO community strategy and represents a key milestone in MedLink’s delivery of high-value healthcare solutions on an enterprise level,” said Ray Vuono, President of MedLink. “SyntraNet is a cloud based Health Information Exchange that can be deployed quickly across the service area of RHIOs, providing incredible value as the community scrambles to provide a financially sensible and scalable interoperable solution to meet the ‘meaningful use’ stipulations necessary to receive federal financial incentives to its member physician and healthcare organizations.”

MedLink and Thrasys will market the cloud based HIE platform to Regional Health Information Organizations and Large Hospital groups as a solution for interoperability, and to provide cloud based applications that leverage both MedLink and Thrasys technologies to streamline wide spread EHR adoption.

About Thrasys, Inc.

Thrasys, Inc. based in San Francisco, California brings innovative solutions to the healthcare market based on breakthrough technologies to rapidly build and deploy highly scalable applications targeted at communities and enterprises. Thrasys solutions for healthcare are based on XNet, an open and standards based application platform to rapidly build and deploy enterprise solutions based on XML services, rich internet application user interfaces, configurable workflows and rules, and interoperability. SyntraNet, based on XNet, is a health information exchange and collaboration network that provides a comprehensive set of applications for care providers, patients, service centers and payers. Please visit www.thrasys.com to learn more.

About MedLink

MedLink is a healthcare IT company that provides the medical community with products and services designed to help create, manage, and share medical information. The company’s flagship product, MedLink TotalOffice EHR 3.1, a CCHIT Certified® 08 Ambulatory EHR, provides physicians with full EHR and practice management functionality. For more information regarding MedLink’s products and services, please visit www.medlinkus.com.

Safe Harbor Statement

This news release may contain forward-looking statements within the meaning of the federal securities laws. Statements regarding future events, developments, the Company’s future performance, as well as management’s expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, outlined in our 2009 Annual Report on Form 10-K available through www.sec.gov. The Company undertakes no obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

SILVER SPRING, MD–(Marketwire – September 2, 2010) –  A new laboratory, designed and built in accordance with international guidelines, opened September 1 in Maseru, Lesotho. The Makoanyane Military Hospital Laboratory now offers an expanded testing menu, including CD4 and Acid Fast Bacilli microscopy, and separate rooms dedicated to specimen reception, microbiology, chemistry, hematology and CD4 testing. The formerly limited, one-room hospital lab was transformed through a collaborative effort of The US Department of Defense and CDC’s Global AIDS Program to support the Lesotho Defense Force’s facility.

The Association of Public Health Laboratories (APHL) provided on-site support and technical assistance to the Lesotho Defense Force, the agency that operates the military hospital, through its cooperative agreement with CDC/GAP in support of PEPFAR.

Senior APHL consultant Kim Lewis worked on-site in Maseru on laboratory design, procurement of equipment and supplies, renovation oversight, organizing laboratory workflow and operations, staff development and initial steps toward WHO Accreditation through implementation of the Strengthening Laboratory Management Towards Accreditation Program. 

APHL will continue to support the new facility by implementing a quality system to assure accurate, reliable and timely test results.

“The laboratory provides access to testing services for a population with high rates of TB and HIV, and enables medical providers to effectively treat these diseases,” said Lewis. “The success of this collaboration is measured in the improved health of the people of Lesotho. The new lab will hopefully affect the well-being of families and lead to a better future for their children. We expect it to serve as a model for other countries.”

The Association of Public Health Laboratories is a national non-profit located in Silver Spring, MD, that is dedicated to working with members to strengthen governmental laboratories with a public health mandate. By promoting effective programs and public policy, APHL strives to provide public health laboratories with the resources and infrastructure needed to protect the health of US residents and to prevent and control disease globally.

Click here to see all recent news from this company

CASCO, ME–(Marketwire – September 2, 2010) –  Camp Sunshine, a one-of-a-kind national retreat in Casco for children with life-threatening illnesses and their families, today announced that Hyundai Hope on Wheels has selected the organization to receive a $100,000 “Hope Grant.” Hope on Wheels is a partnership of 800 Hyundai dealers across the United States and Hyundai Motor America aimed at raising awareness of childhood cancer. Camp Sunshine will use funds from the grant to sponsor two additional oncology sessions at the Camp in 2011.

On Sept. 25 — during National Childhood Cancer Awareness Month — Hope on Wheels will visit Camp Sunshine’s Casco campus and participate in a check presentation ceremony to commemorate the event. Throughout the month, Hope on Wheels will travel to all 68 Hope Grant recipients to present the donations and hear from children, their families and all of those involved in the fight against cancer.

“While we’ve made progress over the last few decades and now have an 85 percent cure rate, cancer still takes more lives than any other childhood disease,” said John Krafcik, President and CEO of Hyundai Motor America. “This September, in support of Childhood Cancer Awareness Month, Hyundai will shine a nationwide spotlight on this cause and provide more than $6 million in grants for pediatric cancer research and support programs. We love taking on big challenges at Hyundai, and we can think of no more worthy challenge than finding a cure for all forms of pediatric cancer.”

Located in Maine’s scenic Sebago Lake region, Camp Sunshine features a 23-acre lakeside campus with private family suites, as well as a climbing wall, indoor swimming pool and computer learning center — all of which are free of charge to all families. To date, Camp Sunshine has welcomed families from 47 states and 17 countries.

“Camp Sunshine is delighted and humbled to receive this generous donation from Hyundai,” said Matt Hoidal, executive director, Camp Sunshine. “This investment will enable us to expand our programs in 2011 and bring nearly 1,000 children and their families much needed respite, support, and hope. We thank Hyundai and their network of dealers in Northern New England and around the country for helping us continue our service and contributions to the cancer community.”

About Camp Sunshine
Camp Sunshine offers children with life-threatening illnesses and their families a place to relax together for a week, and to take a break from the extraordinary demands placed upon them on a daily basis. The year-round program is free of charge and staffed almost entirely by volunteers. It is the only program in the nation whose mission is to address the impact of a life-threatening illness on every member of the immediate family — the ill child, the parents and the siblings. Since its inception in 1984, Camp Sunshine has provided a haven for more than 32,000 individuals from diverse cultural backgrounds. In addition to providing 24-hour on-site medical and psychosocial support, the camp offers a variety of daily activities, including swimming, boating, archery and soccer, and special events such as bonfires and cookouts. To support Camp Sunshine, please call (207) 655-3800 or visit www.campsunshine.org.

About Hyundai Motor America
Hyundai Motor America, headquartered in Fountain Valley, Calif., is a subsidiary of Hyundai Motor Co. of Korea. Hyundai vehicles are distributed throughout the United States by Hyundai Motor America and are sold and serviced through more than 800 dealerships nationwide.

About Hyundai Hope on Wheels
Hyundai Hope on Wheels™ is the united effort of more than 800 Hyundai dealers across the U.S. to raise awareness about childhood cancer and celebrate the lives of children battling the disease. By the end of 2010, Hope on Wheels will have awarded more than $23 million dollars to children’s hospitals and non-profit organizations across the U.S. to support the fight against childhood cancer.

DALLAS, TX–(Marketwire – September 2, 2010) –  Metiscan, Inc. (PINKSHEETS: MTIZ) announced today shareholder points of interest discussed during the Company’s nationwide teleconference yesterday. Mr. Bryan A. Scott, President & CEO, and Mr. Brian Hart, COO of Metiscan, provided deeper insight into its subsidiaries’ markets, products, and near term objectives, as well as Metiscan’s pursuit in listing on the OTCBB.

During the Teleconference, Mr. Scott detailed Metiscan’s corporate structure as the parent company of a portfolio of enterprises with operations in healthcare, healthcare IT, mobile technology and employment services. Metiscan manages all aspects of its subsidiaries and is currently pursuing growing its subsidiary Taptopia through technologies that are unique to its products and through acquisitions that complement its subsidiaries’ operations. Metiscan’s four subsidiaries are FirstView EHR, Inc., Taptopia, Inc., Schuylkill Open MRI, Inc. and Shoreline Employment Services, Inc. Mr. Scott further discussed Metiscan’s recent filing of its registration statement and its goal to meet the OTC Market requirements to qualify for the OTCBB market tier.

Mr. Scott also mentioned how Taptopia was founded in July 2009 with the vision of applying new technologies to the $80 Billion convention, trade show and meeting industry that revolutionize the way show managers and event organizers do business. Mr. Scott stated that, “the industry is greatly in need of technologies, more specifically software technologies, that aid exhibitors and attendees to realize more value from their events, as well as aid show managers with tools that help increase attendance and reduce costs.” He also summarized that Taptopia’s goal is to create and roll out new patent protect software technologies, which Taptopia has in its pipeline.

Bryan Hart, COO of Metiscan, mentioned that the Company is trending in a positive manner. Mr. Hart explained how Metiscan realized approximately $2.5M in revenues for year-end 2009, a 144% increase from year-end 2008. During 2010, the Company’s revenues have continued to increase over the last two quarters. Mr. Hart stated, “This quarter alone we experienced a 47% increase in our revenues, or $165,439 from the same period in 2009.” Mr. Hart also mentioned that during the first half of 2010 Metiscan experienced a 16% increase in its revenues, a $194,111 gain. The Company’s overall revenues as of June 30, 2010 were $1,413,490.

Mr. Hart stressed the importance of how digital medical information, specifically the electronic healthcare record systems FirstView administers and Schuylkill Open MRI recently implemented, saves the medical industry time and money. He stated that, “Metiscan strongly believes that storing medical information digitally, and being able to distribute it electronically, is a great cost savings by itself.” Mr. Hart also mentioned that last year $19 billion in the stimulus package targeted physicians to use electronic health record systems because EHR technology cuts costs, eliminates paperwork and helps doctors deliver high quality, coordinated care to patients. Mr. Hart explained that this will benefit Metiscan both for its imaging center as it relates to the benefit of the operational efficiencies EHR provides, and for FirstView as it relates to the professional Healthcare IT services it provides.

Mr. Hart explained how Metiscan demonstrated positive income from operations during the first half of 2010 totaling $184,464. Mr. Hart mentioned that Metiscan has constantly been focused on increasing operational efficiencies in all of its subsidiaries. Mr. Hart gave the example of how Schuylkill Open MRI moved towards more economical service contracts for maintaining all of its MRI equipment in its diagnostic imaging center and recently implemented a new EHR system. With FirstView, Mr. Hart said it reduced costs related to operating its data center and the amount of personnel needed for its billing and collection activities. He summarized his discussion on Metiscan’s subsidiaries, pointing out that Shoreline, its employment services division, has focused on economies of scale as it relates to personnel resources and benefits.

In closing, Mr. Scott stated, “We are very excited about our business activities here at Metiscan. We have great expectations for our company and our team believes in its future. We have been successful in building a company that is displaying both financial growth and innovation in new products and technologies.”

A recording of Metiscan’s nationwide teleconference will be available on the Company’s website at: www.metiscan.com within the next few days.

About Metiscan, Inc.

Metiscan, Inc. (Metiscan) (PINKSHEETS: MTIZ) is the parent company of a portfolio of enterprises with operations in healthcare, healthcare IT, mobile technology and employment services. Metiscan manages all aspects of its subsidiaries and is currently pursuing acquisitions that complement its subsidiaries’ operations. Metiscan’s subsidiaries include FirstView EHR, Inc., Taptopia, Inc., Schuylkill Open MRI, Inc., Shoreline Employment Services, Inc. For more information visit www.metiscan.com

Safe Harbor Statement: Certain of the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Metiscan’s actual results to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. The Company does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

LONDON–(Marketwire – September 2, 2010) –  Genome Research Group (GRG) (PINKSHEETS: KKUR) recently announced its intended merger with ChromoCure, Inc. and consolidation of the operations and technologies of both groups. Genome Research Group personnel have assumed all executive and board duties and have no current or planned operations in the USA.

The company intends to open permanent offices in the United Kingdom as well as establish the first of several planned research labs and testing partners.

To date, the Company has not been able to secure its previously anticipated investment capital due to the declining USA economy and capital markets. The Company believes it has now secured satisfactory capital commitments and will proceed with its business plan accordingly.

The Company’s objectives are:

1. Recapitalize the company’s stock structure and change the company’s trading symbol to trade under “Genome Research Group.”

2. Establish business offices and permanent address in the United Kingdom with the most likely location being London.

3. Structure the company’s operations as decentralized management with multiple operational hubs and team members around the world.

4. Secure initial research lab space for the Company’s ongoing research and development for both its cancer imaging systems as well as its therapeutic protocols and animal modeling experiments.

5. Appoint industry leaders to the Company’s Board of Advisors.

6. Partner with cancer labs and pathology labs within the European Union. The Company does not believe the USA healthcare market will be an open market inviting of innovation or new ideas. The Company has no immediate plans to seek partnerships within the USA due to healthcare over-regulation and control by the US government.

7. Complete and deploy company branding, image, and professional design of marketing and educational materials.

8. File updated financial information with appropriate legal opinion letter to achieve “Current” reporting status. The Company has no immediate intent to become a “SEC Reporting” company due to the massive expense and liability of that status.

The Company intends to release updates from time to time as these actions are completed.

About Genome Research Group
Genome Research Group develops and provides proprietary cancer detection systems and related therapeutic technologies. The Company’s proprietary cancer detection system locates and measures unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company’s proprietary Therapeutic Modeling Protocols provide statistical modeling and prediction tools for the measurement and monitoring of cancer progression and remission. GRG owns proprietary techniques for non-toxic and non-invasive cancer therapy utilizing hypothermic modulation and resonance.

Safe-Harbor Statement
This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

SPRINGFIELD, OH–(Marketwire – September 2, 2010) –  AdCare Health Systems, Inc. (NYSE Amex: ADK), a recognized innovator in senior living and health care facility management, has closed the lease of three nursing homes according to the previously announced agreement to lease five additional nursing homes in Georgia.

The three nursing homes, which have been leased under a 10-year term, have an aggregate of 280 beds that generate approximately $15.5 million in annualized revenue. With the addition of these three facilities and other transactions closed earlier in the year, AdCare’s estimated annualized revenue run-rate now exceeds $79 million, as compared to $26.7 million for the year ended 2009.

Upon closing of the lease transaction, AdCare provided the lessor $195,000 for the first month’s lease payment and a portion of the security deposit, with the balance of $337,000 to be paid over five months comprising the balance of the security deposit and an amount equal to two months lease payments.

“This transaction is the third we’ve closed since we began our M&A campaign at the end of last year,” said Chris Brogdon, AdCare’s vice chairman and chief acquisitions officer. “We expect all of these facilities to be significant cash generators for AdCare, especially as they come under our highly capable management and benefit from our larger economy of scale.”

“As we work toward closing the currently pending transactions we’ve announced, including the lease of the remaining two nursing homes in Georgia, additional opportunities continue to emerge in the southern region of the U.S.,” said Brogdon. “We are working to establish the terms and necessary financings for several new potential acquisitions in our pipeline of equal or greater potential.”

Brogdon joined AdCare last September when the company announced a new M&A growth strategy to build upon its strong reputation for operational efficiency and high-quality living environments.

About AdCare Health Systems
AdCare Health Systems, Inc. (NYSE Amex: ADK) is a recognized innovator in senior living and health care facility management. AdCare develops, owns and manages assisted living facilities, nursing homes and retirement communities, as well as provides home health care services. Since its inception in 1988, AdCare’s mission has been to provide the highest quality of healthcare services to the elderly. For more information about AdCare, visit www.adcarehealth.com.

Important Cautions Regarding Forward-Looking Statements
 Statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of federal law. Such statement can be identified by the use of forward-looking terminology, such as “believes,” “expects,” “plans,” “intends,” “anticipates” and variations of such words or similar expressions, but their absence does not mean that the statement is not forward-looking. Statements in this announcement that are forward-looking include, but are not limited to, statements that the company expects all of these new facilities to be significant cash generators for AdCare. Such forward-looking statements reflect management’s beliefs and assumptions and are based on information currently available to management. The forward-looking statements involve known and unknown risks, results, performance or achievements of the Company to differ materially from those expressed or implied in such statements. Such factors are identified in the public filings made by the Company with the Securities and Exchange Commission and include the Company’s ability to secure lines of credit and/or an acquisition credit facility, find suitable acquisition properties at favorable terms, changes in the health care industry because of political and economic influences, changes in regulations governing the industry, changes in reimbursement levels including those under the Medicare and Medicaid programs and changes in the competitive marketplace. There can be no assurance that such factors or other factors will not affect the accuracy of such forward-looking statements.

Click here to see all recent news from this company

REDWOOD CITY, CA–(Marketwire – September 1, 2010) – AeroScout, the leading provider of Unified Asset Visibility for the healthcare industry, today announced continued strong growth in its healthcare business, extending its global lead in the healthcare market. 2009 was a record year for AeroScout healthcare revenue, and subsequent to that, the first half of 2010 represented the strongest two quarters in the company’s history for AeroScout’s Healthcare Real-Time Location System (RTLS). In those two quarters, AeroScout received more than 200 orders for its healthcare solutions, which provide real-time visibility into the location, status and condition of assets, patients and staff, from healthcare organizations around the world. One of the main reasons for the rapid adoption is that, with AeroScout’s Wi-Fi RFID solutions, organizations are able to leverage their existing, standard Wi-Fi infrastructures instead of deploying and maintaining separate proprietary networks. 

“In addition to its comprehensive set of Healthcare RTLS solutions and integration capabilities, AeroScout offers hospitals the opportunity to save money while reducing risk and complexity by using their Wi-Fi networks instead of proprietary networks,” said Gregg Malkary, Managing Director of Spyglass. “This means its clients don’t need to purchase, wire and maintain an overlay network, and it has led to rapid growth for AeroScout and Wi-Fi RFID over the past few years.”

Complementing the Wi-Fi advantages, other factors that have contributed to AeroScout’s increasing market leadership include its track record with top hospitals and healthcare systems around the world, its robust suite of solutions, and the ease with which AeroScout solutions integrate with other healthcare information systems, hospital equipment and business processes.

AeroScout has completed implementations at hundreds of healthcare organizations, covering every major region of the world — North America, Australia, Europe, Asia, the Middle East and Latin America. The experience gained over the years from these customers and deployments has continued to increase AeroScout’s healthcare expertise and customer base. Examples of global healthcare customers include:

• Adventist Health System, Winter Park, Florida, USA
• Macquarie University Hospital, Sydney, Australia
• GZA Hospital Group, Antwerp, Belgium
• Akita University Hospital, Akita, Japan
• Hospital Israelita Albert Einstein, São Paulo, Brazil

AeroScout’s comprehensive solutions allow customers to work with a single, proven provider and implement one platform for all current and future asset, patient and staff visibility needs. This includes enterprise-wide asset and people tracking, room-level location, bay-level (sub-room) resolution, optional chokepoint detection, condition monitoring and passive RFID applications.

Focusing on the needs of its global healthcare customers, AeroScout is continuously expanding and enhancing its robust set of healthcare applications, which includes Asset Management, Condition Monitoring, Patient Flow and Patient & Staff Safety. For example, the company recently enhanced its Patient Flow and Patient & Staff Safety solutions by designing and producing the world’s smallest Wi-Fi Tag for patients and staff. AeroScout also supplemented its Condition Monitoring offerings with Humidity Monitoring Solutions, which include Wi-Fi Tags and end-user software.

AeroScout’s range of integrations with healthcare information systems is the broadest in the RTLS market. AeroScout offers integrations with nurse call systems, maintenance management systems, infusion pumps, security and building automation systems, VoIP communication devices and more. For example, AeroScout now integrates with the Rauland-Borg Responder 5 Nurse Call system to enable improved clinician efficiency and workflow. AeroScout also provides MobileView for VoIP Phones, which delivers AeroScout’s end-user software on VoIP communication devices to enhance staff productivity, mobility and communication.

“To serve our multiplying healthcare customer base, we continue to develop and enhance solutions to drive additional value for our clients,” said Yuval Bar-Gil, CEO of AeroScout. “Hospital and healthcare organizations across the globe are using AeroScout’s Wi-Fi-based solutions to reduce capital and operational expenses, increase staff efficiency, facilitate regulatory compliance and improve patient care.”

About AeroScout
AeroScout is the market leader in Unified Asset Visibility solutions. Customers improve operational efficiency using AeroScout products that leverage standard Wi-Fi networks to track and manage the location, condition and status of mobile assets and people. AeroScout’s global customer base consists of leading hospital, manufacturing and logistics organizations, including many of the Fortune 500. The company invented the first Wi-Fi-based Active RFID tag, and today is widely recognized as leading the market in number of deployments and tags shipped. Headquartered in Redwood City, California, AeroScout has offices in Europe, the Middle East, Asia, Australia and Latin America. For more information, please visit www.aeroscout.com.

AeroScout is a registered trademark of AeroScout, Inc. Wi-Fi is a trademark of the Wi-Fi Alliance. All other trademarks are the property of their respective owners. Information is subject to change without notice.

CENTERVILLE, MA–(Marketwire – September 1, 2010) –  UV Flu Technologies, Inc. (OTCBB: UVFT) (the “Company”) announced today that the improved features added to its UV-400 air purifier have been generating a surprising amount of interest from distributors.

The Company recently began coating the inside of its patented UV-400 cartridge with a thin layer of the photo-catalyst Titanium Dioxide (TiO2). Combined with the germicidal UV lamps contained within the cartridge, and moisture in the air, the hydroxyl radicals produced by the TiO2 accelerate the breakdown of molecular bonds present as odors or in the case of Volatile Organic Compounds (“VOC”). These compounds are converted into harmless water vapor and carbon dioxide, which results in significantly reducing the concentration and effects of odors and VOC’s.

“Volatile Organic Compounds, such as acetone, formaldehyde, benzene, as well as hundreds of other compounds, are surprisingly common in offices or households, and can be harmful in even small concentrations to people with respiratory problems, especially children and the elderly,” stated Jack Lennon, President of UV Flu Technologies. “Carpets, building materials, cleaning supplies, paints and varnishes, vinyl floors and furniture, air fresheners, copiers and printers, pesticides, secondhand smoke, wood burning stoves, nail polish remover and hair products; are all just a small sample of the products emitting VOC’s, many of which cause allergic reactions, as well as many of them containing known carcinogens. The UV-400 product has undergone laboratory tests which show the concentration of VOC’s are reduced significantly with each pass, which is repeated several times per hour in a typical room.”

“Many of our customers are very excited about this feature,” commented Bill Fegley, President of Puravair, a major distributor of UV Flu products. “The reduction of the concentration of these compounds and odors is considered very important to a wide array of our customer base, such as salons, health clubs, funeral homes, restaurants and athletic facilities. This feature, combined with the UV-400’s proven ability to kill bacteria, make it a compelling purchase for any location that commonly finds these types of airborne contaminants present in the course of their day-to-day operations.”

Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.
—————————–
John J. Lennon, President & CEO

Click here to see all recent news from this company

DALLAS, TX–(Marketwire – September 1, 2010) –  Metiscan, Inc. (PINKSHEETS: MTIZ) is pleased to announce that the Company will be hosting a Nationwide Teleconference today, Wednesday, September 1, 2010 at 4:15 PM (Eastern Daylight Time) to update the financial community on points of interest that affect Metiscan and its shareholders. The Company will be discussing its recent operational accomplishments that have transpired over the previous six months as well as providing insight into objectives Metiscan has outlined for the near term.

If you would like to participate in the Nationwide Teleconference with Metiscan at 4:15 PM EDT today, please dial 1-800-871-9060, pass code 943301958#.

“This teleconference is very timely for Metiscan; we have accomplished many goals during the last six months that we want to share with the investment community and we look forward to discussing what’s next for the Company in a public forum,” stated Bryan A. Scott, CEO & President of Metiscan, Inc.

The Nationwide Teleconference will be hosted and moderated by Marc Jablon, CEO of Big Apple Consulting USA. The featured speakers for Metiscan, Inc. will be Bryan A. Scott, President, CEO & Director, and Brian Hart, COO.

About Metiscan, Inc.
Metiscan, Inc. (Metiscan), (PINKSHEETS: MTIZ), is the parent company of a portfolio of enterprises with operations in healthcare, healthcare IT, mobile technology and employment services. Metiscan manages all aspects of its subsidiaries and is currently pursuing acquisitions that complement its subsidiaries’ operations. Metiscan’s subsidiaries include FirstView EHR, Inc., Taptopia, Inc., Schuylkill Open MRI, Inc., Shoreline Employment Services, Inc. For more information visit www.metiscan.com.

Safe Harbor Statement: Certain of the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Metiscan’s actual results to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. The Company does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

FOOTHILL RANCH, CA–(Marketwire – September 1, 2010) –  Össur, a global leader in non-invasive orthopaedics, today announced a new strategic alliance with Hely & Weber, a supplier of innovative, high-quality braces and supports. Founded in 1992, founders John Hely and Jim Weber have a combined 76 years of experience in the orthopedic and sports medicine industry. The Hely & Weber line includes renowned products such as the Titan Wrist Brace, Shields Patella Stabilizer, Knapp Hinged Knee, and 24 patented soft bracing products which have a long history of successful clinical performance.

Beginning September 1, Össur will participate in an agreement to distribute Hely & Weber’s line of soft goods through Össur’s Group Purchasing Organization (GPO) contracts. Hely & Weber’s line will also be available through three of Össur’s representatives: Team Makena (So.CA), Synergy Orthopedics (East PA, NJ), and Dashe Orthopedic Supplies (TX, AR, OK).

“We welcome the opportunity to provide Hely & Weber’s high-quality products to our customers,” said Mahesh Mansukhani, Össur Americas president. “The addition of Hely & Weber products to our line expands our ability to provide innovative products that drive successful patient outcomes for our customers.”

John Hely, CEO of Hely & Weber, commented, “We are excited about the opportunity to work with Össur to strengthen our market presence. Össur is a leading company that is well positioned to continue its success in the non-invasive orthopaedic area.”

About Össur

Össur (NASDAQ/OMX: OSSR) is a global leader in non-invasive orthopaedics that help people live a life without limitations. Its business is focused on improving people’s mobility through the delivery of innovative technologies within the fields of braces, supports, prosthetic limbs and compression therapies. A recognized “Technology Pioneer,” Össur invests significantly in research and product development; its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Össur’s educational programs and business solutions. Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. Össur Americas’ headquarters are based in Orange County, CA.

Click here to see all recent news from this company

LOS ANGELES, CA–(Marketwire – September 1, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (www.mmrglobal.com) expands its advertising of Personal Health Records products and services (www.mymedicalrecords.com) on national television tonight, September 1, 2010, at 6 pm EDT, in “The Spirit of Mississippi,” on the Hallmark Channel. The Company also announced that starting today, a nationwide radio Listener Loyalty Program was launched with Clear Channel Communications in which listeners will be directed to MMR’s website to take advantage of the Company’s end of Summer Labor Day promotion of a 30-day trial and $25 toward the cost of their next doctor visit (www.mmrvideos.com).

Robert H. Lorsch, Chairman and Chief Executive Officer of MMRGlobal, said, “Labor Day weekend was chosen to launch this radio marketing campaign because it is a great time to reach consumers about the importance of having a Personal Health Record when traveling with the family.”

Lorsch continued, “The people of Mississippi and the entire Gulf region are making progress in rebuilding their lives. Our products offer the reliability and resiliency needed to recover more quickly from any emergency or disaster. With MyMedicalRecords, individuals and families can have direct access to their most important documents, including insurance policies, deeds of trust, wills, birth certificates and advance directives, in addition to their medical records. Everything is located in one secure, convenient location accessible from any Internet connection anywhere in the world.”

About Clear Channel Communications, Inc.

Founded in 1972, with headquarters in San Antonio, TX, the Company broadcasts in over 50 countries through its divisions, Clear Channel Radio: San Antonio, TX and Clear Channel Outdoor: San Antonio, TX and reaches more than 154 million people, or 75% of the 18+ U.S. population, operating over 800 radio stations reaching more than 97 million listeners every week. With international partners, the Company owns and operates more than 140 radio stations in Australia and New Zealand. Premiere Radio Networks syndicates 90 radio programs and services to more than 5,000 radio stations affiliations reaching over 190 million listeners a week.

About MMRGlobal, Inc.

MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mymedicalrecords.com and view the videos at www.mmrtheater.com.

Forward-Looking Statements. Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. MMRGlobal, Inc. disclaims any intent or obligation to revise or update any forward-looking statements. These forward-looking statements are based on MMRGlobal, Inc.’s reasonable expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related to changes in MMRGlobal, Inc.’s business prospects, results of operations or financial condition, government regulation, television programming changes, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.’s public filings with the U.S. Securities and Exchange Commission.

Click here to see all recent news from this company

EVANSTON, IL–(Marketwire – September 1, 2010) –  Custom health communications company StayWell Custom Communications (SCC), a division of MediMedia USA, has announced that Bob Noel has joined the organization as Vice President of Professional Services.

In his new role, Noel will spearhead the company’s consulting services to help clients achieve best of class implementation of StayWell Custom Communications’ content and cross-media solutions in order to achieve business results.

Noel brings a wealth of professional services experience to the position, including work as
a consultant with more than 100 hospitals and healthcare organizations. He was a co-founder and Executive Vice President of Greystone.Net, Inc., where he provided consulting services to assist clients in the implementation and integration of the Greystone online consumer health information libraries.

Noel’s previous experience also includes working as a Senior Manager in the health care consulting practice of Ernst & Young and as an Assistant Administrator at the University of Alabama in Birmingham Medical Center. He earned a Master’s degree in Healthcare Administration from the University of Alabama in Birmingham. 

“We are extremely pleased to welcome Bob Noel to our team and look forward to the value he’ll bring our clients in their implementation of our solutions,” said StayWell Custom Communications president and CEO Trent Sterling. “With more options than ever for integration of our content across multiple channels and strategies — including SEO, social media, mobile and electronic medical records — it’s increasingly important that our clients undertake a rigorous approach to integration in order to realize the full value of our solutions.”

About StayWell Custom Communications

StayWell Custom Communications is the leader in custom health content solutions delivered via a variety of sophisticated technology platforms. Our interactive offerings include robust web platforms, online health libraries, e-mail and SMS (or mobile) marketing programs, and an extensive range of multimedia tools including video, podcasts and animations. The company serves hundreds of clients representing several channels in the healthcare industry: hospitals and health systems; health plans; employers; and retail organizations. StayWell Custom Communications also offers a comprehensive range of print and print/interactive integrated solutions to meet a broad range of clients’ marketing and communication needs. 

For more information visit www.staywellcustom.com.

About MediMedia

Headquartered in Yardley, PA, with 1,700 employees in offices throughout the U.S., MediMedia changes consumer and professional behaviors through superior engagement, education and end-user preferences. Our health information services group creates, publishes, distributes, and syndicates on and off-line health information to help consumers make informed health decisions on behalf of a variety of sponsors, including providers — both hospitals and physicians, payers, and online media companies. Our health management services group provides population health management services which help consumers lower their health risk, enabling employers to lower their risks, utilization and ultimately their health care expenses. And finally, our professional segment derives its revenues from providing online/off-line professional promotion, engagement, and education services targeted to healthcare professionals and their patients.

MediMedia is a Vestar Capital Partners portfolio company.

SAN DIEGO, CA–(Marketwire – September 1, 2010) –  Recombinant human beta-interferon reduces the frequency of multiple sclerosis (MS) exacerbations and improves MS outcome measures. Unfortunately, current beta-interferon drug products form aggregates that provoke a neutralizing antibody response in MS patients, significantly reducing the effectiveness of the drug.

In a Journal article titled: “n-Dodecyl-?-D-Maltoside Inhibits Aggregation of Human Interferon-?-1b and Reduces Its Immunogenicity” which appeared in the Journal of Neuroimmune Pharmacology, published online on June 7, 2010 scientists from a leading US University Medical School report that addition of a patented ProTek® excipient, a pharmaceutical grade of dodecyl maltoside developed by Aegis, inhibits aggregation and prevents development of antibodies in vivo suggesting a route to greatly improved beta interferon formulations. The abstract of the scientific report may be viewed online at: http://www.springerlink.com/content/v46614510n311211/.

According to Dr. Edward T. Maggio, CEO of Aegis Therapeutics, “Aggregation-induced immunogenicity is a problem for many protein therapeutics, reducing drug effectiveness and in extreme instances, causing life-threatening adverse reactions as with erythropoietin and Factor VIII. And because protein aggregation also adversely affects manufacturing process yields and drug potency it has become a major concern for pharmaceutical formulators worldwide.”

ProTek® excipients are being used to prevent aggregation of monoclonal antibodies, human growth hormone, parathyroid hormone, and insulin, as well as a number of undisclosed proprietary peptide or protein therapeutics now in development.

About Aegis Therapeutics
Aegis Therapeutics commercializes its patented drug delivery and drug formulation technologies through product specific licenses. Our Intravail® technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection with exceptionally high and unmatched bioavailability. Our ProTek® technology provides proprietary, easily manufacturable, aqueous dosage forms that are stable at elevated temperature and that reduce unwanted immunogenicity of many protein and peptide therapeutics.

SAN CLEMENTE, CA–(Marketwire – August 31, 2010) –  Micro Identification Technologies, Inc. (OTCBB: MMTC) is a California-based public company that has developed, patented and produces a rapid microbial identification (ID) System that revolutionizes the bacteria ID process and can annually save thousands of lives and tens of millions of healthcare dollars. The MIT 1000 System identifies bacteria in minutes, not days, and at significant cost per test savings when compared to any conventional method — it is not reliant on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis — requiring only clean water and a sample of the unknown bacteria. Revenues for all rapid testing methods exceed $5 billion annually — with food safety accounting for over $3 billion — having expanded at a rate of 9.2 percent annually since 1998. Current growth projections are at 10.2 percent annually reaching $6.2 billion by 2013 and driven by major health, safety and homeland security issues.

MIT, to meet this growing demand, announces today that it has made significant manufacturing progress since its initiation of a manufacturing alliance with OSI Optoelectronics (OSIO), a subsidiary of OSI Systems, to produce the MIT 1000 System. OSIO has manufacturing facilities in California, Malaysia and India. “We are pleased to work with MIT as we feel their innovative product will become a valuable tool to help prevent widespread bacterial contamination in the future,” stated Manoocher Mansouri, OSIO’s President.

“All of OSIO’s world class facilities are ISO 9001:2000 certified, FDA registered and GMP compliant making them the perfect company to fabricate MIT’s systems for food safety applications as well as planned pharmaceutical and clinical diagnostic applications,” stated John Ricardi, MIT’s Executive Vice President and Chief Operating Officer. Mr. Ricardi further added that “While we are predicting quantity deliveries of the MIT 1000 System by the end of this year, initially the systems will be built in OSIO’s California facility, as volume increases, fabrication will move to one of their lower cost overseas facilities enabling MIT to improve future profit margins.” For more information on OSI Systems, visit the company’s website at www.osi-systems.com

The MIT 1000 Systems, in limited production during this last year, have had several distinguished users, including the U.S. Department of Agriculture, Japanese Ministry of Food Safety, University Putra Malaysia and several local contract bioscience testing laboratories. MIT’s Chairman Michael Brennan stated, “We have a small and growing backlog, are in discussions with several potential customers and are on track with this year’s goal to begin quantity deliveries by year’s end, and in turn need to increase our system support and microbiological research capabilities in conjunction with helping improve the food industry’s safety capabilities.”

To fund these activities, MIT has entered into a three-year $5,000,000 equity agreement with the Boston-based private equity firm, Dutchess Capital — the underlying S-1 Registration Statement was recently approved by the Securities Exchange Commission (SEC). MIT’s Chief Executive Officer, Michael Brennan, stated, “We have been very pleased working with Dutchess which has an excellent track record in the investment banking industry and has been a leading provider of private equity for over 10 years. Their successful background was the primary reason we selected them to be one of our partners.”

Chris Quin, Dutchess Vice President of business development stated, “We are excited to work with MIT as they continue to execute their business plan, develop further applications and increase market penetration of their laser-based, rapid microbial identification technology.” For more information on Dutchess Capital, visit the firm’s website at www.dutchesscapital.com

About Micro Identification Technologies:

The MIT 1000 System can identify bacteria in less than five minutes after culturing at a cost of less than 10 cents per test and is a certified AOAC Research Institute (RI) test method of Listeria, one of three bacteria (the others are Salmonella and E.coli) that are responsible for most of the worldwide food contamination events. The Company is in the process of preparing the MIT 1000 System to become AOAC RI certified later this year for the presence of all “three” bacteria with a single mouse click. The AOAC RI Report and Certification are available from the Company. www.aoac.org 

Further, MIT has demonstrated the ability to detect and identify, within several minutes, the microbes Escherichia coli, Listeria, Salmonella, Staphylococcus aureus, MRSA and other pathogenic bacteria. MIT recently performed over 300 tests for the identification of these contaminants and scored over 95 percent in accuracy. The System’s database currently enables the identification of over twenty species of bacteria and is easily expandable. This identification process has also been verified by North American Science Associates, Inc. (NAMSA), an independent, internationally recognized bioscience testing laboratory. The NAMSA Test Report is available from the Company and, in MIT’s opinion, documents the accuracy, speed and cost effectiveness of the MIT System over conventional processes. www.namsa.com

Please visit our website: www.micro-identification.com

This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission, referencing: “MMTC”

NEW YORK, NY–(Marketwire – August 31, 2010) –  On August 31st Fly for MS takes off from New York on a thrilling humanitarian mission to 30 countries in North America, Europe and Asia where the team will fly MS patients for treatment, and share the joy of flying with more than 100 people with MS to raise awareness for the challenges faced by over 2.1 million fighting this debilitating disease.

Fewer than 300 have flown a small plane for such a distance, and none for a humanitarian mission, compared to over 4,000 people who successfully climbed Mount Everest.

The mission will debut with a flight above Manhattan with Tom Clyne of New York, a representative from the U.S. National MS Society suffering from MS.

“Using my cane, I’m reminded of my MS with every step I take. Being up in the air with Andrei and the Fly for MS team, I can be free, even for a few moments. It’s a wonderful and exciting project he’s undertaking to bring awareness to the challenges people with MS experience every day of their lives,” says Tom.

Fly for MS is the brainchild of pilot Andrei Floroiu, a former Wall Street investor focused on biotechnology companies. In his profession he realized from interviews with over 600 MS patients and doctors how little the public knows about MS and recognized the need for a unique event to inspire compassion and action.

MS patients face harsh realities including lack of services due to budget cuts and limited availability of proper treatment. Ignorance of MS often forces people with MS to withdraw from society, hiding an illness poorly understood.

MS is a debilitating disease that affects 1.5 million people in North America and Europe alone. The symptoms of MS are cruel and include paralysis, speech impairment, and blindness. MS typically strikes people between the ages of 20 – 50 and renders 60% of those touched disabled over time. MS also affects an estimated 50,000 children globally.

With no known cause or cure in sight, awareness will move MS higher on government agendas, change employers’ attitudes and educate the world how to help. Awareness has a multiplier effect on future research funding.

“Through this unprecedented journey we aim to expose the contrast between the ultimate freedom of flying and the limitations of those living with MS, and reach new, broader audiences that other efforts have not been able to in the past,” says Floroiu.

“As a volunteer driven organization, it is bold, imaginative and independent projects such as Fly for MS that raise awareness for the challenges of living with MS and the funds needed to move us closer to a world free of the disease. The Society certainly encourages this heart-felt endeavor,” says Joyce Nelson, President and CEO of the U.S. National MS Society.

On certain legs of the tour, MS specialists, advocates, public figures and journalists will fly along.

Competitions are organized in certain countries for those that want a flight in the Fly for MS plane and the team will join fundraisers and awareness events across Europe.

Updates and photographs from the mission will be posted daily at www.flyms.org, Twitter, and Facebook. For more information visit: http://www.flyms.org/fly-for-multiple-sclerosis-schedule.html

Click here to see all recent news from this company

DALLAS, TX–(Marketwire – August 31, 2010) –  Metiscan, Inc. (PINKSHEETS: MTIZ) is pleased to announce that the Company will be hosting a nationwide teleconference on Wednesday, September 1, 2010 at 4:15 PM (Eastern Daylight Time) and will discuss points of interest that affect Metiscan and its shareholders. The Company will be discussing its recent operational accomplishments that have transpired over the previous six months as well as providing insight into objectives Metiscan has outlined for the near term.

The nationwide teleconference will be hosted and moderated by Marc Jablon, CEO of Big Apple Consulting USA. The featured speakers for Metiscan will be Bryan Scott, President, CEO & Director, Janine Frieh, CFO & Director, and Brian Hart, COO & Director.

Space is limited on the call-in lines, therefore in order to participate please call 407-389-5900 and ask for investor relations to make a reservation. If you have a particular question for Mr. Scott, Ms. Frieh or Mr. Hart, please email questions in advance to [email protected].

About Metiscan, Inc.

Metiscan, Inc. (Metiscan), (PINKSHEETS: MTIZ), is the parent company of a portfolio of enterprises with operations in healthcare, healthcare IT, mobile technology and employment services. Metiscan manages all aspects of its subsidiaries and is currently pursuing acquisitions that complement its subsidiaries’ operations. Metiscan’s subsidiaries include FirstView EHR, Inc., Taptopia, Inc., Schuylkill Open MRI, Inc., Shoreline Employment Services, Inc. For more information visit www.metiscan.com

Safe Harbor Statement: Certain of the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Metiscan’s actual results to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. The Company does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

NATICK, MA–(Marketwire – August 31, 2010) –  Interbit Data, a leading provider of software and services for improving healthcare efficiency, today announced it has been named to Inc. Magazine‘s exclusive list of the 5,000 fastest growing private companies in the United States for the second year in a row. The company ranked No. 1902 as a result of achieving over 142% growth from 2006 to 2009, a significant move up from its ranking of No. 2909 on the 2009 Inc. 5000 list. This growth places Interbit Data at No. 152 in the health industry ranking and No. 64 among Boston, MA area companies.

“Our continued growth during this economy is not only proof of our staying power, it is confirmation of the significant value our software delivers in terms of time and cost savings,” said Arthur Young, president of Interbit Data. “We are dedicated to helping healthcare providers improve the level of care by addressing their challenges with streamlining operations, distributing patient data and reports, and ensuring access to critical patient records during system downtimes.”

Since 1997, Interbit Data has sold its software solutions for improving operational efficiency to over 650 healthcare providers and organizations in the U.S., Canada and U.K. The company offers three types of solutions that contribute to increased productivity, reduced costs, and, ultimately, better and more consistent patient care:

• Information distribution — automates the secure transfer of information over the Internet in multiple formats (print, fax, email or file), easily integrating it into physician practices’ electronic medical records (EMRs) using the industry standard HL7 format.
• Business continuance — ensures up-to-date patient data is readily available in the event of a network or system outage.
• Scheduling and workforce automation — automates manual scheduling, enabling organizations to easily implement a complex schedule and efficiently manage staff.

The 2010 Inc. 5000 serves as a unique illustration of the profound changes taking place in the U.S. economy. Despite the fact that most of this year’s measuring period of 2006-2009 took place during the latest recession, aggregate revenue among the companies on the list actually increased to $321.6 billion, up more than 50 percent from last year. The effects of the recession are seen, however, in the median three-year growth rate, which dropped to 96 percent from last year’s 126 percent.

This year’s Inc. 5000 employ a record 1.4 million people, up from one million on last year’s list. The Health sector is the top employer with 287,726 jobs, followed by Business Products & Services (230,066), Food & Beverage (108,344), Human Resources (107,924), and Retail (96,858).

The top five industries by total revenue are Business Products & Services ($84.7 billion), Health ($48.3 billion), Consumer Products & Services ($26.4 billion), Retail ($22.3 billion), and Government Services ($15.1 billion).

Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found on www.inc.com/5000.

Inc. 5000 Methodology
The 2010 Inc. 5000 is ranked according to percentage revenue growth when comparing 2006 to 2009. To qualify, companies must have been founded and generating revenue by June 30, 2006. Additionally, they had to be based in the United States, privately held, for profit, and independent — not subsidiaries or divisions of other companies — as of December 31, 2009. (Since then, a number of companies on the list have gone public or been acquired.) The minimum revenue required for 2006 is $80,000; the minimum for 2009 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. The top 10 percent of companies on the list constitute the Inc. 500, now in its 29th year.

About Inc. Magazine
Founded in 1979 and acquired in 2005 by Mansueto Ventures LLC, Inc. (www.inc.com) is the only major business magazine dedicated exclusively to owners and managers of growing private companies that delivers real solutions for today’s innovative company builders. With a total paid circulation of 712,647, Inc. provides hands-on tools and market-tested strategies for managing people, finances, sales, marketing, and technology. Visit us online at Inc.com.

About Interbit Data
For more information about Interbit Data and its NetSolutions healthcare IT products, visit the company Website at www.interbitdata.com.

Click here to see all recent news from this company

CALGARY, ALBERTA–(Marketwire – Aug. 31, 2010) – This Saturday, Recovery Acres (Calgary) Society and Moscow Ballet will host open auditions for Swan Lake on Saturday, September 4, 9:00AM at Ballet Classique, 176 Bedford Drive NE. The accepted applicants will perform on November 22 & 23 in Moscow Ballet’s Great Russian Swan Lake at 7:30PM, at the EPCOR CENTRE’S Jack Singer Concert Hall.

Swan Lake auditions are for pre-professional ballet students, ages thirteen to sixteen with pointe experience. Twelve applicants will be chosen to dance in one scene of Swan Lake with the 40-strong professional, Russian trained cast. Applicants must dress in dance attire and be prepared to dance en pointe. For local information, contact Sara Lynne Dewer at (403) 245 4346.

Nataliya Miroshnyk, a Russian trained soloist with Moscow Ballet, will conduct the audition and work with the selected students in rehearsal at a later date. During her audition tour, she will work one-on-one with young dancers in Calgary, Medicine Hat, Regina, Saskatoon, Surrey, Winnipeg and Thunder Bay. Nataliya, a graduate from the well-respected Kiev Academic Choreographic School in Ukraine, trained under the honoured A.G. Kalchenko.

“Having Nataliya lead auditions is both exciting and inspirational,” says Sara Lynne Dewer, Ballet Classique’s director. “Not only does she expose dancers to authentic Russian form, but this opportunity epitomizes inclusive artistic collaboration – providing a flavour of local, amateur energy in this production, is a true gift for these children, and for audiences.”

The Moscow Ballet Canadian tour is presented by Recovery Acres (Calgary) Society, one of Canada’s most effective, non-profit, addiction treatment facilities. A portion of tour proceeds will support capital funding for the facility’s needed $10M expansion project.

As one of the most revered ballets in the world, Swan Lake premiered over a century ago in Russia and remains a timeless classic, expressing a range of human emotions accented by Tchaikovsky’s luminous score.

Ticket prices range from $45-$140 and are now available through www.epcorcentre.org.

To view promotional reel, please visit: Great Russian Swan Lake.

For more information on the Moscow Ballet Canadian Tour, please visit www.moscowballetcanada.com.

About Nataliya Miroshnyk – Visiting Ballet Mistress

Nataliya enjoyed a tremendous amount of post-graduate experience throughout the world during her time with the Odessa State Academic Opera and Ballet Theatre. She was with the Company for almost twelve years and traveled to many countries including China, Japan, Germany, Lebanon and Finland. 

Nataliya also worked with La Classique, a well-known classical ballet troupe based in Moscow. Working with La Classique gave her the opportunity to perform in front of new audiences throughout the United Kingdom, Italy and Norway.

About Moscow Ballet – The Company

Moscow Ballet (est. 1993) is a Massachusetts-based touring company, whose roster features graduates of Perm, Yaganova, Moscow State Academic Choreographic and Kiev schools from Russia each year. Created by award-winning theatrical producer and Juilliard alumni, Akiva Talmi, the company tours upwards of 70 US cities per year, recently branching into a growing number of Canadian cities.

Through the Moscow Ballet’s Educational Outreach Program, “Celebrating Children: The Arts Can Make a Difference”, the company engages local children to audition and appear with professional dancers in the roles of cygnets, snowflakes and butterflies. www.nutcracker.com.

About Recovery Acres (Calgary) Society – Tour presenter & beneficiary

In partnership with the Moscow Ballet, Calgary-based Recovery Acres Society is raising $10 million dollars of capital funding to build a new alcohol and drug treatment facility for men. Once complete, the current building will be renovated to accommodate female clients. Wait lists are ever growing and the need, particularly for woman, is consistently on the rise.

Recovery Acres (Calgary) Society is a North American leader in the treatment of alcohol and drug addiction. Their proven Recovery Model serves as a best practices model for treatment facilities and clients from around the world. The affordability of its program opens the reality of rehabilitation to a broad spectrum of clientele. www.recoveryacres.org.

MINNEAPOLIS, MN–(Marketwire – August 31, 2010) –  Sunshine Heart Inc., a global medical device company focused on innovative technologies for moderate heart failure, today announced that its C-Pulse^® Heart Assist System has been successfully implanted using a minimally invasive thoracotomy procedure at Saint Luke’s Mid America Heart and Vascular Institute in Kansas City, MO. The C-Pulse System is the first known mechanical heart assist system to be implanted using a minimally invasive thoracotomy technique. The device was inserted through a small, pacemaker-like incision between the patient’s ribs, leaving the sternum intact. To date, thirteen patients have been implanted under Sunshine Heart’s existing worldwide C-Pulse study protocols. The FDA approved IDE feasibility study will include a total of 20 patients to evaluate the performance of this device for patients with moderate heart failure.

The C-Pulse Heart Assist System is designed to treat patients suffering from the debilitating effects of moderate heart failure caused by a failing left ventricle (the left heart chamber). The C-Pulse System features a unique balloon counterpulsation technology that is designed to assist the left ventricle by reducing the workload required to pump blood throughout the body. In addition, it increases blood flow to the coronary arteries. Combined, these potential benefits may help reverse the heart failure process or maintain the patient’s current condition, thereby preventing the need for later stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. 

“We are pleased to welcome Saint Luke’s Mid America Heart and Vascular Institute to our C-Pulse clinical trial,” said Dave Rosa, CEO of Sunshine Heart. “These latest procedures accomplish our goal of successfully implanting the C-Pulse System through a mini-thoracotomy surgical method. As we approach the end of our feasibility study, we are encouraged by the interest of our centers and we remain dedicated to developing this minimally invasive, cost-effective treatment that is intended to relieve the symptoms of moderate heart failure.”

Sanjeev Aggarwal, MD, Director of Mechanical Circulatory Support at Saint Luke’s Mid America Heart and Vascular Institute in Kansas City, Missouri, performed the procedures. In addition to performing the first minimally invasive thoracotomy C-Pulse procedures, Dr. Aggarwal has also successfully performed a minimally invasive hemi-sternotomy (mini-sternotomy) C-Pulse procedure at St. Luke’s Hospital.

“The C-Pulse Heart Assist System represents an important advance in the treatment of patients suffering from heart failure,” commented Dr. Aggarwal. “In our initial procedure last month, the clinical effects were dramatic, with an almost immediate improvement in cardiac performance and the patient’s functional status. I am very encouraged that we were able to perform our two subsequent implants utilizing a minimally invasive pacemaker-like incision, without dividing the sternum. This offers the opportunity to provide patients suffering from moderate heart failure with a means of mechanical circulatory support through a truly minimally invasive, low risk procedure with a short recovery period.”

“Today, there are few treatment options for the millions of Class III/IVa moderate heart failure patients who have achieved the maximum benefits of drug and pacemaker therapy yet still suffer from symptoms such as shortness of breath and reduced mobility,” said Dr. Andrew Kao, Medical Director of Heart Transplantation at St. Luke’s Mid America Heart Institute. “I am very pleased that the new C-Pulse therapy is being studied at St. Luke’s Hospital as we believe this device can make a tremendous difference for these patients who have limited treatment options.”

The C-Pulse System is an earlier intervention than other mechanical therapies, such as LVADs. This device does not make direct contact with patient’s blood and it can be turned on or off at any time allowing patients intervals of freedom to perform certain activities. The C-Pulse System can also be implanted as a minimally invasive procedure, thereby potentially reducing procedural time, hospital stays, overall cost and patient risk as compared to a traditional sternotomy.

Sunshine Heart’s FDA approved IDE study is available to men and women between the ages of 18 to 75 who suffer from Class III/ambulatory Class IV heart failure and for whom standard drug therapy has failed. The study monitors each patient’s performance with the C-Pulse System at one-month, three-month and six-month intervals to assess risks and potential benefits. Each patient’s physical endurance, quality of life and cardiac performance will also be specifically monitored.

About the C-Pulse Heart Assist System
The C-Pulse Heart Assist System uses proprietary balloon counterpulsation technology to increase the amount of blood pumped by the heart and to reduce the workload on the heart. The C-Pulse System is implanted in the patient’s chest through a sternotomy or through a small incision when performed as a minimally invasively procedure. During the procedure, there is no need to place the patient on a heart-lung machine as the patient’s heart remains beating continuously.

Once implanted, the C-Pulse cuff is positioned on the outside of the patient’s ascending aorta above the aortic valve. An ECG sensing lead is then attached to the heart to determine timing for cuff inflation and deflation in synchronization with the heartbeat. The C-Pulse cuff and electrical leads are connected to a single line that is run through the abdomen to connect to a power driver outside the body. Because the C-Pulse System remains outside the blood system, there is potentially less risk of blood clots and stroke in comparison to other mechanical devices that reside or function in the bloodstream.

About Sunshine Heart
Sunshine Heart (ASX: SHC), a global medical device company focused on innovative technologies for the treatment of moderate heart failure, is commercializing the C-Pulse^® Heart Assist System, a minimally invasive, implantable, non-blood contacting, heart assist therapy for the treatment of moderate heart failure. The C-Pulse System relieves the symptoms of heart failure through the use of counterpulsation technology which enables an increase in cardiac output, an increase in coronary blood flow and a reduction in the heart’s pumping load. The Company has received approval from the US Food and Drug Administration (FDA) to conduct a 20-patient U.S. clinical trial with the C-Pulse^® System and the study has achieved more than fifty percent enrollment as of August 2010. Sunshine Heart, Inc. is a Delaware-based Corporation headquartered in Minneapolis with a subsidiary presence in Australia. The Company has been listed on the ASX since September 2004. For more information, please visit www.sunshineheart.com.

Click here to see all recent news from this company

RALEIGH, NC–(Marketwire – August 31, 2010) – Healthcare experts got a dose of Lean Six Sigma principles when Rucker and Associates presented its best industry practices to ISH, Inc. to help them better understand the power of Lean Six Sigma for efficiency and productivity. Florida-based ISH, Inc. has developed hundreds of quality improvement initiatives at many of the nation’s leading healthcare organizations. Working with Rucker has been their first exposure to Lean Six Sigma principles in action.

ISH, Inc. is a leading provider of office processing and time management software for the healthcare industry. Bonnie Smith of Rucker and Associates handled the presentation to administrators at ISH, Inc., providing them with information on ways to integrate Lean Six Sigma principles into everyday operations to improve performance. 

According to Smith, the strategy at ISH, Inc. focused on lead-time to reduce defects and improve the company’s workflow. “Finding ways to improve what we refer to as ‘profit-busters’ will not only decrease waiting times and improve patient care but save a healthcare organization money,” she said.

Smith’s seven profit-busters that plague the industry include: waiting, over-processing, over-production, indecision, hand-offs, loop-backs and excess inventory.

She uses Rucker case examples to explain: “Hospitals that use Lean Six Sigma have saved $16 million through efficiency improvements that include: reducing emergency room wait times by one hour, reducing turnaround times for patient tests from 74 to 40 minutes, lowering in-patient registration questions from 39 to six, and more timely accounts receivables,” she said.

“Controlling these efficiencies helps healthcare organizations save valuable time and resources, which impacts the bottom line,” said Smith, an efficiency expert who played a pivotal role in creating the synthesis of Lean principles and Six Sigma tools now known as Lean Six Sigma.

Healthcare organizations are more actively using Lean processes to improve clinical trials and supply chain management. According to Rucker statistics, Lean Six Sigma has helped hundreds of healthcare organizations improve quality measures and increase bottom line profitability.

Rucker and Associates is a high-performance consultancy dedicated to helping companies discover dramatic new efficiencies using Lean Manufacturing and Six Sigma improvement methodologies. Rucker’s hands-on mentoring process with clients produces dramatic results — training teams to accelerate change and implement continuous improvement. Every Rucker project features an unconditional guarantee. http://ruckerassociates.com/.

Headquartered in Fairfield, N.J., ISH, Inc. is a leading national provider of professional services for healthcare, including: Perioperative, Sterile Processing, ED, EMR, Supply Chain, Finance, HR/PR, Time and Attendance, Scheduling, Document Imaging, Interim Management. ISH has delivered business improvement solutions and information technology implementations to prominent healthcare providers throughout the nation since 1989. With a staff of more than 150 professionals, an extensive best practice library developed from over 500 clients, and a powerful program management methodology, ISH is positioned to deliver the results you need when you need them. http://www.ishinc.com.

Click here to see all recent news from this company

KANKAKEE, IL–(Marketwire – August 31, 2010) –  Riverside Medical Center, whose mission is to meet the health and well-being needs of the communities it serves, provided more than $36.7 million in community benefit in 2009. This high quality southern Chicago suburbs healthcare provider receives no payment for a wide variety of vital programs and services devoted to individuals and families through the medical center’s service area. As one of the top hospitals in Illinois, Riverside is committed to making quality healthcare available to everyone, regardless of their economic condition. 

The income, employment and insurance status of residents of Kankakee County results in the hospital caring for a large number of patients who are uninsured or underinsured, or for whom public program reimbursement is inadequate to cover costs. Of the $36.7 million of community benefit that Riverside Medical Center provided in 2009, over $18.1 million of the total covered costs was for subsidized health services. That included Medicaid services and community health centers in Kankakee, Momence and Hopkins Park. This figure also includes New Life Center, ambulance services, health screenings, physician recruitment and health care education, among other services.

As a nonprofit organization, after paying expenses, Riverside reinvests any excess revenue back in the organization to pay for capital improvements. Riverside also allocates portion of this money to services that benefit patients: free care for patients who cannot pay, subsidized care for patients whose government insurance does not cover all of Riverside’s costs, and critical medical services that operate at a financial loss but are necessary for the overall health and well-being of the community.

Riverside also acts as an economic engine for Kankakee County and the surrounding areas like southern Will County healthcare. Not only do they provide care for those who are not financially able to afford it, but they also help create more jobs and economic growth in our community. Riverside not only has a significant impact on the health and welfare of residents, but also has a large impact on the local economy, both of which are definitely for the better. If you are in need of any sort of medical services, Riverside Medical Center is here to make sure you get the best care provided anywhere.

To learn more about the quality services offered by Riverside Medical Center, visit www.RiversideMC.net or call (815) 933-1671.

Click here to see all recent news from this company

TUSTIN, CA–(Marketwire – August 31, 2010) –  Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today it has resumed collaborations with Mayo Collaborative Services, Inc. to conduct a clinical study for the validation of RPC’s US FDA-approved Onko-Sure® in vitro diagnostic (IVD) cancer test as a useful tool in colorectal cancer (CRC) recurrence and treatment monitoring.

Over 1,000 colorectal patient samples with various disease stages will be tested in parallel by RPC and Mayo Clinic to directly compare the results of the Onko-Sure® test with the Carcinoembryonic Antigen (CEA) test. The primary goal of the study is to determine whether Onko-Sure® is more effective than CEA at detecting early stage colorectal cancers. CEA has been reported to misdiagnose a disproportionate number of early stage cancers. Detecting cancer in earlier stages can lead to improved accuracy in the treatment, monitoring and recurrence monitoring of the disease in cancer patients. This head-to-head study is scheduled to be completed in the fourth quarter FY2010 and data generated will be provided to Mayo physicians and investigators for publication in medical journals.

“We are very excited to resume collaboration with Mayo’s Validation Support Services team. This marks a critical and potentially market changing milestone for Radient Pharmaceuticals and for our Onko-Sure® IVD cancer test,” commented Douglas MacLellan, Chairman and CEO of RPC. “Through this work, we expect to validate the efficacy of RPC’s Onko-Sure® test as a critical tool for treatment, monitoring, and/or recurrence monitoring of colorectal cancer suffers.”

RPC’s Onko-Sure® IVD cancer test is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection and monitoring of the treatment and/or recurrence of various types of cancer. The test enables physicians and healthcare professionals to effectively detect and/or monitor certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure® is cleared by the US FDA for detection during colorectal cancer treatment and/or for recurrence monitoring in colorectal cancer patients and by Health Canada for the detection, treatment and/or recurrence monitoring of lung cancer. For more information visit www.onko-sure.com.

RPC Contact Information:
For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its Onko-Sure® In Vitro Diagnostic cancer test. The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve patient outcomes. Radient Pharmaceutical’s current Onko-Sure® cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.

About Mayo Validation Support Services:
Mayo Validation Support Services, an affiliate of Mayo Clinic, based in Rochester, Minnesota and assists pharmaceutical, biotechnology and diagnostic companies in validating the clinical significance of emerging biomarkers and technologies. Mayo’s contribution of well-annotated biospecimens and clinical follow-up data support the development of individualized medicine, one of Mayo’s strategic initiatives.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

HILO, HI–(Marketwire – August 31, 2010) – –Pacific Quest, a unique, internationally recognized wilderness therapy program for struggling teens and young adults, located on the Big Island of Hawaii, is pleased to announce the launch of their new website http://www.pacificquest.org.

Mike McKinney, Co-Founder and Executive Director of Pacific Quest, commented, “We’re very pleased with the look and feel of the site… the new site demonstrates how far we have come in a short amount of time — from an emerging program with bold ideas in 2004, to today, one of the most innovative and respected wilderness programs in the industry.”

Notable features on the newly updated website include:

• Richer Content — Enhanced internal pages, including updated information on the Program, Health and Wellness, Clinical Services, and Admissions
• Social Media — Stay connected with Pacific Quest through their blog, Facebook or Twitter pages
• Expanded Media Library — See the wilderness therapy programs close up with more pictures and videos
• Improved Navigation — Move more easily through the site to find what you are looking for
• CMS — A new content management system allows for updates to the site in real time 

Mark Agosto, Outreach Director, added, “We hope the new website can be an effective resource for teens and young adults, and their families, as well as with our network of professionals. We are thrilled to share a little bit more about Pacific Quest with the community.”

For more information regarding Pacific Quest, please visit www.pacificquest.org or contact Mark Agosto, Outreach Director, at (808) 937-5806 or via email at [email protected].

To read more on this topic, visit: http://www.pacificquest.org/news/1/196/Pacific-Quest-Wilderness-Therapy-Program-Announces-New-Website/.

About Pacific Quest:

Pacific Quest is an outdoor behavioral healthcare (“wilderness therapy”) and sustainable treatment program for struggling teens and young adults, located on the Big Island of Hawaii. The program offers a clinical, yet holistic approach to treatment — going beyond traditional therapy and teaching sustainable life skills. Owned and operated by a veteran team of professionals with over 200 years of combined program experience, Pacific Quest offers a unique approach to treatment that is individualized for each student. Through experiential education, clinical services, a dedicated approach to health and wellness, and sustainable gardening, Pacific Quest provides a structured yet flexible outdoor therapy environment that serves the individual needs of each student, cultivating a therapy experience with personal meaning and importance.

Click here to see all recent news from this company

GLOSTRUP, DENMARK–(Marketwire – August 31, 2010) – Dako, a leading player in the field of advanced staining, launches a new staining solution for H&E. The pathology laboratories today are facing many constraining factors; finding and retaining trained laboratory staff is more difficult, and the need for more efficient and cost effective solutions is essential. Dako has designed a new H&E solution to meet the needs of the customer. Today Dako is launching the CoverStainer helping to optimize the laboratory process and delivering high quality, consistent results.

“At Dako, it all starts out with quality. We have transformed all our knowledge within IHC and Special Stains into the H&E area. We have done this not just by focusing on the instrument like many of our competitors do, but we have taken it one step further and are providing a full solution with reagents and instrumentation that work together perfectly. First we standardize and then we automate to secure quality at every step,” Lars Holmkvist, Dako’s CEO, says. He continues: “We are trying to help the laboratory with the most efficient means, so they can control the lab at the highest level of quality, and deliver fast answers to the patients.”

What is H&E staining?
When a patient is confronted with a possible cancer diagnosis, a biopsy is performed and a tissue specimen is taken. The specimen is tested in a pathology laboratory, using a process referred to as Hematoxylin and Eosin or H&E staining. The H&E stain is the first stain in the diagnostic process where a pathologist confirms or rules out a possible disease. The patient will either be able to go home with a ‘normal’ result, or they will be told that more confirmatory testing is required. A majority of the H&E samples can be diagnosed immediately. The pathologist can confirm or rule out a cancer diagnosis.

Prof. Dr. Hermann Herbst at Vivantes in Berlin, Germany has been using the Dako CoverStainer for four months in their routine operations, shares his findings: “You want to have a standardized process. At Vivantes we did a test of around 3000 slides, and our measurements show that the Dako CoverStainer saves us about 43% of the time needed in the older procedure. Our previous process required a lot of attention on the part of the technicians, and this lead to a lot of variation in the results. Now with the Dako CoverStainer, slides have a consistent quality, which makes it a lot easier.”

The launch of the Dako CoverStainer is part of the Dako strategy to be the preferred partner to the pathology laboratory. The addition of H&E staining to the Immunohistochemistry and Special Stains product lines, that Dako has mastered for more than four decades, allows Dako to become a complete staining partner.

Facts about the Dako CoverStainer
The Dako CoverStainer is an automated instrument transforming the H&E staining process by combining the entire process from baking through coverslipping to determine the patient’s first and most critical diagnosis of cancer. The Dako H&E solution combines the advanced Dako CoverStainer with Dako Ready-to-Use (RTU) Reagents and a Dako validated pre-optimized staining protocol. The Dako CoverStainer can process up to 240 H&E slides per hour and the first results in 46 minutes which makes it the fastest in its automated class.

AUSTIN, TX–(Marketwire – August 30, 2010) – Drummond Group Inc., the trusted software testing lab, is one of the first to be approved by the Health and Human Services, Office of the National Coordinator for Health IT (ONC) to be an ONC-Authorized Testing and Certification Body (ONC-ATCB) to certify Complete EHRs and all EHR Modules for both ambulatory and inpatient settings. Eligible professionals (EPs), eligible hospitals and critical access hospitals (CAHs) participating in Medicare and Medicaid programs to collect incentive payments through meaningful use of electronic health record (EHR) technology must use EHR technology certified by an ONC-ATCB.

“Drummond Group has been working diligently for many months to meet the stringent criteria set forth by ONC to become certified as an ONC-ATCB, and we are very pleased that ONC has recognized our efforts and our competency to be an approved testing and certification body,” says Rik Drummond, CEO Drummond Group Inc. “We are pleased to offer over ten years of software testing and certification experience in other industries to Healthcare. After executing several pilots on existing EHR products and working with industry consultants, our organization is more than prepared to test and certify healthcare products.”

“The ONC accreditation is an acknowledgement that Drummond Group is fully qualified to meet the needs of EHR meaningful use stage one testing and certification. We highly commend the work of ONC and their accreditation process which tested the details of our testing and certification process and our industry knowledge. Having started new tests with other industries, we found this approval process to be the most demanding and the most thorough we have encountered. With our approval as an ONC-ATCB, EHR vendors and implementers can have full confidence in our testing and certification services, and we look forward to beginning testing with the many EHR software companies that have contacted us.”

To learn more about Drummond Group’s EHR testing and certification program including test registration and related pricing, please visit: http://www.drummondgroup.com/

For more information on ONC’s ATCB program, please visit: http://healthit.hhs.gov/

About Drummond Group
Drummond Group Inc. (DGI) is the trusted test lab which works with standards groups, software/firmware vendors and industry groups to drive adoption of standards by offering global interoperability, conformance testing and certification. DGI facilitates these testing services under association-branded certification programs and its own Drummond Certified® program. Founded in 1999, DGI also represents best-of-breed in strategic interoperability testing recognizing the challenges of interoperability for industry over the product life cycle.

• DGI provides interoperability certification for M2M or business-to-business (B2B) standards which are used for the Fortune 500 financial information flow, representing billions of dollars per year. Cyber security of data transfer is critically tested.
• DGI manages the KANTARA INITIATIVE Global Interoperability Test Program for Identity information exchange for the US government and the other global leaders in identity.
• DGI facilitates software audits of the Controlled Substance Ordering System (CSOS) software managed in compliance with the DEA regulations.
• Drummond Certified® software and firmware is required in RFPs around the globe to ensure seamless, secure, interoperable products which make implementation easy, thereby significantly reducing costs.
• DGI was recently awarded two Department of Energy stimulus funded Smart Grid demonstration projects. DGI’s role in both projects relates to the interoperability and certification of Smart Grid technology.

Click here to see all recent news from this company

SUWON, SOUTH KOREA–(Marketwire – August 30, 2010) – Neurotech Pharmaceuticals Co., Ltd. has begun dosing in the Phase 1 clinical testing of AAD-2004. AAD-2004 was developed as a dual function drug to remove free radicals and PGE₂, the key mediators of nerve injury in Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). The Phase 1 clinical trial was initiated to evaluate the safety, tolerability, and pharmacokinetics of AAD-2004 in healthy volunteers in April, 2010. The first two cohorts of the clinical study have been successfully completed without serious adverse events.

About FREE RADICALS AND PGE₂ IN NEURODEGENERTIVE DISEASES
Free radicals and PGE₂-mediated inflammation are expected to play a central role in the neurodegenerative process occurring in neurodegenerative diseases including AD, PD, and ALS. However, no drugs have been developed to prevent free radicals in the brain of AD, PD, and ALS due to poor blood-brain barrier permeability and adverse effects. Long-term use of conventional nonsteroidal anti-inflammatory drugs (NSAIDs) has been limited by the risk of cardiovascular infarction and thrombosis as well as gastrointestinal complications. Currently there are no FDA-approved drugs to protect nerve cells against toxic free radicals and inflammation evolving in the nervous system of patients with AD, PD, and ALS.

About AAD-2004
The scientific founders of Neurotech Pharmaceuticals discovered a novel chemical library on the premise that a single agent combining the anti-inflammatory attributes of aspirin with powerful anti-oxidant efficacy would constitute effective disease modifying therapeutics for nerve protection in neurodegenerative diseases, based on the additive/synergistic neuroprotective effects via compromising free radicals and inflammation. With leading supports via 21C Frontier R&D Program in Neuroscience from Ministry of Education, Science, and Technology, a National Drug Discovery Program from Ministry of Health and Welfare, and Ajou University in South Korea, Neurotech Pharmaceuticals launched an Anti-Alzheimer’s Drug discovery program. AAD-2004 was selected as a final drug candidate based upon safety and efficacy study in animal models of AD that improved cognitive function far better than antioxidants or NSAIDs as well as memantine, an FDA approved drug for the symptomatic treatment of AD. The therapeutic potential of AAD-2004 has been verified in animal models of ALS, PD, and major depression. Unlike conventional NSAIDs causing gastric damage, however, AAD-2004 did not produce gastric damage even at a dose 400-fold higher than maximally effective doses in animal models.

“While NASIDs cause gastric and cardiovascular risks by preventing production of prostaglandins PGI₂ as well as PGE₂ by inhibiting cyclooxygenases, AAD-2004 selectively prevents PGE₂ production as an inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), the terminal isomerase catalyzing conversion of PGH₂ to PGE₂, at nanomolar concentrations, which explains why AAD-2004 is safer than NSAIDs. In addition, the potent spin trapping property of AAD-2004 provides additional efficacy and safety,” said Byoung J. Gwag, Ph.D., CEO of Neurotech Pharmaceuticals and Professor at Department of Pharmacology of Ajou University School of Medicine. “The marked safety and efficacy in preclinical studies make AAD-2004 a promising drug candidate to advance into clinical trials. We are so pleased to see safety profile of AAD-2004 in human healthy volunteers exposed to doses higher than maximally effective doses in preclinical studies.”

About Neurotech Pharmaceuticals
Neurotech Pharmaceuticals was founded to develop drugs for the treatment of neurological diseases on the basis of the close collaboration of basic and clinical academic teams in 1998. In addition to AAD-2004, Neu2000, a moderate NMDA receptor NR2B-selective antagonist and potent antioxidant, has been developed as a drug candidate for stroke, spinal cord injury, acute myocardial infarction, and burn injury. Nonclincial and human phase I studies in the United States demonstrate that Neu2000 is safe (therapeutic index = 35 – 800 depending on types and severity of diseases) and thus can be advanced into human phase II study. ND-07 has been developed to treat inflammatory diseases including pancreatitis, inflammatory bowel disease, rheumatoid arthritis, and pain and is near the end of preclinical study.

Click here to see all recent news from this company

TORONTO, ONTARIO–(Marketwire – Aug. 30, 2010) – Sunnybrook Health Sciences Centre will offer people a sneak peak of its greatly anticipated, new birthing facilities and neonatal intensive care units. Sunnybrook’s new facilities encompass more than 120,000 sq. ft. of space making it one of the largest and most comprehensive facilities of its kind in Canada. The Women & Babies Program will deliver 4,250 babies every year in this new space and will care for 1 of every 5 babies born in Ontario who weigh less than 3 pounds.

WAYNE, PA–(Marketwire – August 30, 2010) –  The Clinical and Laboratory Standards Institute (CLSI) and Association of Public Health Laboratories (APHL) are offering a teleconference to the health care community to learn more about the different considerations surrounding acceptance criteria on point-of-care (POC) glucose devices. The teleconference on September 30 is titled “POC Glucose Devices: Perspectives From the Hospital, Government, and Vendor.”

The US Food and Drug Administration (FDA) recently held a public forum on glucose meter devices to gather wide perspectives on the clinical requirements for blood glucose meter accuracy and precision. Using the CLSI consensus process in gathering balanced viewpoints from industry, professional societies, and government bodies, this educational program will provide an overview of different perspectives surrounding the glucose device acceptance criteria for both self-testing and professional use, and possibly expand the presentations at the most recent FDA public meeting.

“This teleconference will not only highlight the need for glucose meter accuracy and precision, but also discuss the studies that have been performed and what is to come from the many organizations and associations looking into guidelines around this issue,” said Marcy Anderson, MS, MT(ASCP), Director of Development and Education, CLSI.

The teleconference will help participants to describe differences in the use of glucose meters in self-testing vs hospital or professional settings. They will also understand the differences between the perspectives of the government agency, professional expert, and POC glucose vendor representative. There will be an opportunity to ask questions at the end of the program.

Speakers include:

• Alan Cariski, MD, JD
  VP, Worldwide Medical Affairs, LifeScan Inc., Milpitas, California

• Courtney Harper, PhD
  Director, FDA Division of Chemistry and Toxicology Devices, Silver Spring, Maryland

• Mitch Scott, PhD
  Director, Division of Laboratory Medicine at Washington University Hospital, St. Louis, Missouri

Upcoming point-of-care teleconferences:

• Deciding Factor: Selection Criteria for Point-of-Care Testing Devices (588-614-10)
  September 16 • 1:00-2:00 PM Eastern (US) Time

• POC Glucose Devices: Perspectives From the Hospital, Government, and Vendor (588-623-10)
  September 30 • 1:00-2:30 PM Eastern (US) Time (1.5 contact hours)

• Getting It Right: Approaches to Reducing Errors at the Point of Care (588-616-10)
  October 7 • 1:00-2:00 PM Eastern (US) Time

Register for the upcoming teleconferences at www.aphl.org/clsi. Discounts are offered for conference series registration.

APHL is approved as a provider of continuing education programs in the clinical laboratory sciences by the American Society for Clinical Laboratory Science (ASCLS) P.A.C.E.^® Program. Participants will be awarded contact hours for each program they successfully complete. P.A.C.E.^® is accepted by all licensure states except Florida. Florida continuing education credit will also be offered.

CLSI is a volunteer-driven, membership-supported, nonprofit organization dedicated to developing standards and guidelines for the health care and medical testing community through a consensus process that balances the perspectives of industry, government, and the health care professions. For additional information on CLSI, visit the CLSI website at www.clsi.org or call 610.688.0100.

Click here to see all recent news from this company

SAN FRANCISCO, CA–(Marketwire – August 30, 2010) –  Catholic Healthcare West (CHW), the nation’s eighth largest health system, today announced that its severe sepsis prevention initiative has saved an additional 991 lives and reduced severe sepsis inpatient mortality rate by 33 percent at the end of three years.

“A core tenant of the health care reform plan enacted by Congress is that we can improve quality while also reducing costs,” says Lloyd H. Dean, CHW President/Chief Executive Officer. “The results of this program clearly demonstrate those achievements are possible.”

CHW launched the three-year initiative in July 2007 with the goal of reducing its inpatient severe sepsis mortality rate by five percent across its 41 hospitals in California, Arizona, and Nevada by 2010.

“This is a remarkable expression of CHW’s mission to deliver excellent care,” says Robert Wiebe, MD, CHW’s Chief Medical Officer. “The collaborative effort amongst our outstanding physicians, nurses, and hospital staff has shown tangible improvements in care. We are diagnosing sepsis earlier, treating it more aggressively, and saving lives.”

Sepsis is the body’s overwhelming response to a serious bacterial infection. It can start in a single area in the body or can be widespread in the bloodstream. If not diagnosed early and treated quickly, sepsis can rapidly lead to organ failure and death. According to the national Surviving Sepsis Campaign, there are more than 750,000 cases of severe sepsis annually in North America with 210,000 fatalities, making it the number one cause of inpatient mortality.

Using the Surviving Sepsis Campaign recommendations, as well as the Institute for Health Care Improvement’s collaborative improvement methods, CHW caregivers and staff focused on early recognition of severe sepsis patients, increasing the use of aggressive and appropriate treatment protocols, educating healthcare professionals, monitoring compliance to treatment guidelines, and facilitating data collection for the purposes of improvement and feedback.

“This is innovative and groundbreaking work,” said R. Phillip Dellinger, M.D., a leader in the Surviving Sepsis Campaign, professor of medicine at University Medicine and Dentistry in New Jersey, and the director of critical care for Cooper University Hospital in Camden, New Jersey. “CHW’s caregivers have demonstrated the power of a well-organized quality program that both reduces morbidity and mortality while also achieving significant cost savings.”

Each CHW hospital has a multi-disciplinary team comprising physicians, nurses, respiratory therapists, pharmacists, and other clinicians that implement an early resuscitation ‘bundle’ — a series of evidence-based measurable treatments that have proven effective when implemented together — during the first six hours a patient is diagnosed with sepsis. The bundle consists of measuring the patient’s blood lactate levels and blood cultures, administering appropriate antibiotics within the first hour of a patient presenting to the emergency department and administering appropriate treatments for low blood pressure. 

Because sepsis is such a widespread and serious problem in the inpatient setting, studies have shown that treating it more effectively will result in lower health care costs. In three years, CHW estimates its severe sepsis prevention resulted in a savings of more than 36 million in direct variable costs.

“By standardizing this early resuscitation bundle throughout our system, CHW is able to deliver the appropriate care to our patients when they need it, avoiding lengthy and costly hospital stays,” says Dr. Wiebe.

In its nine Sacramento and San Francisco Bay Area hospitals, CHW has received a two-year grant totaling $1.8 million from the Gordon and Betty Moore Foundation to support the expansion of sepsis prevention nursing education. Utilizing the grant and a portion of matching funds, CHW has hired an analyst, paid for innovative sepsis education services and has developed a comprehensive sepsis education program.

“The Gordon and Betty Moore Foundation is pleased to be supporting this important initiative, which has made a significant and positive impact on the lives of patients and their families,” said Marybeth Sharpe, Betty Irene Moore Nursing Initiative Program Director. “We congratulate the CHW hospitals on implementing evidence-based practices for identification and treatment of sepsis and recognize the critical role of CHW’s frontline nurses and other clinicians in this effort.”

About Catholic Healthcare West
Catholic Healthcare West (CHW) is the eighth largest hospital system in the nation and the largest not-for-profit hospital provider in the West. Founded in 1986, the CHW network of more than 10,000 physicians and approximately 54,000 employees serve a population spanning 22 million people at 41 hospitals across California, Arizona, and Nevada. CHW is committed to delivering compassionate, high-quality, affordable healthcare services with special attention to the poor and underserved. In 2009, CHW provided $1.2 billion in charity care, community benefits, and unreimbursed patient care. For more information, please visit our website at www.chwHEALTH.org.

TAMPA, FL–(Marketwire – August 30, 2010) –  Sage North America today announced that its Sage Healthcare Division has released Sage Intergy version 6.10 and the new Sage Intergy Meaningful Use Edition. This Sage Intergy Meaningful Use Edition features the components required for physicians to be eligible for federal electronic health records (EHR) incentives, a key provision of the 2009 American Reinvestment and Recovery Act of 2009 (ARRA). 

Under ARRA, physicians and other eligible professionals may qualify for bonus payments from Medicare and Medicaid in exchange for demonstrating “meaningful use” or a certified EHR system.

Sage Intergy is a synergistic clinical, financial and administrative solution that helps physicians to improve the quality and efficiency of care they deliver. The Sage Intergy family of products includes integrated practice management, electronic health records, clinical and business intelligence and tools for online patient engagement. Providers can access Sage Intergy from multiple practice locations, from home, or other remote locations either through a central patient database server, or as a Sage-hosted solution on a monthly subscription basis. 

Sage Intergy Version 6.10 includes enhancements designed to meet key industry certifications, such as the CCHIT 2011 Ambulatory EHR certification and upcoming meaningful use certification. The Meaningful Use Edition expands on the core functionality in v6.10 by providing physicians with additional tools for patient engagement and meaningful use reporting.

“In this combined release, Sage is introducing exciting and innovative solutions that will not only help our customers take full advantage of stimulus dollars, but also greatly enhance the practice experience for patients and physicians,” said Tony Ryzinski, Senior Vice President of Marketing and Product Management with Sage.

Most significant in this latest Sage Intergy release is a new “MU dashboards” feature. This user-friendly analysis tool is used by providers and practices to track performance against clinical quality measures included in the meaningful use guidelines (such as the percentage diabetic of patients with a hemoglobin A1C of less than or equal to 7 percent). The MU dashboards also allow providers to scorecard performance against indicators that measure how they use the system in relation to the meaningful use criteria (for example, for what percentage of patients they maintain an active problem list).

Version 6.10 also includes enhancements designed to further refine interoperability between Sage Intergy and health information exchanges. Expanding on the already considerable list of online services available to patients from the Sage Intergy Practice Portal, Sage has added the ability for patients to view statements and pay bills online and receive secure health reminders from their providers.

Ryzinski said Sage will be ready for meaningful use certification “as soon as a certification body is announced.”

“Once our industry gets past this crucial milestone, it will become increasingly important for healthcare providers and technology vendors alike to understand the broader context of meaningful use,” said Ryzinski. “Stimulus dollars are only an incentive to help providers acquire the technology needed to continue their work to transform healthcare and, ultimately, improve healthcare outcomes for patients while creating practice efficiencies. Federal healthcare reform will drive the meaningful adoption of technology and in turn, should allow physicians to refocus on providing care and improving lives through delivery of care in a time when they are constantly forced to meet non-care demands on their time.”

View Sage Healthcare Division YouTube interviews.
View Sage Healthcare Division information.

About Sage North America
Sage North America is part of The Sage Group plc, a leading global supplier of business management software and services. Sage North America employs 4,000 people and supports 3.1 million small and midsized business customers including approximately 80,000 physicians. The Sage Group plc, formed in 1981, was floated on the London Stock Exchange in 1989 and now employs 13,100 people and supports 6.2 million customers worldwide. For more information, please visit the website at www.sagenorthamerica.com.

© 2010 Sage Software, Inc. All rights reserved. Sage, Sage Software, Sage logos and the Sage product and service names mentioned herein are registered trademarks or trademarks of Sage Software, Inc. or its affiliated entities. All other trademarks are the property of their respective owners.

RESEARCH TRIANGLE PARK, NC–(Marketwire – August 30, 2010) –  Patient recruitment is not the first step in a clinical trial, but well-designed recruiting could be the most important piece. Companies have only scratched the surface of the potential benefits of deep patient understanding to more accurately develop protocols that will meet enrollment targets, according to consulting firm Cutting Edge Information.

According to the upcoming study, “Clinical Trial Patient Recruitment: Accelerate Enrollment, Increase Retention and Reduce Costs,” 72% of respondents perform pre-project research into patient emotion and motivation. But much of that research is ‘surface deep,’ according to industry participants.

“The more information trial designers have about the patient population, the more likely you are to design a study that meets all enrollment goals,” said Jason Richardson, president of Cutting Edge Information. “More nuanced demographic research saves dollars as coordinators put limited funds into the right recruiting channels.”

Project partners pointed to geographically focused recruitment as a significant potential advantage in patient enrollment. Identifying patient clusters aids in clinical site management, helps determine ideal patient incentives and lets the clinical team communicate directly with local advocacy groups.

Thinking like a patient means heavily weighing emotional motivators. Benchmarking partners mentioned common considerations including:

• Are patients embarrassed by their condition?
• Will daily office visits be too painful a reminder that they are living with the disease?
• Will they feel altruistic in joining a study?
• Will the opportunity to increase the scientific understanding of a disease resonate with them?

More experienced patient recruitment specialists are better prepared for such issues, the study suggests. A clinical trial team may push for additional office visits, for example, while a recruitment specialist can identify the point at which site visit frequency will increase drop-out rates. In such situations, the team can identify the best trial protocols to meet the needs of all stakeholders.

“Knowing your patient volunteers and making a strong effort to think like them ultimately helps teams better meet the many challenges of study recruitment,” added Richardson.

Cutting Edge Information (http://www.cuttingedgeinfo.com/) is a consulting firm serving the life science industry. For more information about clinical trials management, contact Elio Evangelista at 919-433-0214 or [email protected]. For media information, contact Stephanie Swanson at 919-433-0212 or [email protected].

Click here to see all recent news from this company

MARKHAM, ONTARIO–(Marketwire – Aug. 30, 2010) – Extendicare Real Estate Investment Trust (“Extendicare REIT” or the “REIT”) (TSX:EXE.UN) today announced the appointment of Margery Cunningham, CFA, to its Board of Trustees, effective immediately, for a term to expire at the next annual meeting of unitholders, whereupon Ms. Cunningham will stand for election.

Margery Cunningham brings with her invaluable experience as a highly regarded analyst within the health care sector. Ms. Cunningham was with Lehman Brothers for 11 years beginning in 1997, most recently as Managing Director and Global Head of Product Training, overseeing training for over 28,000 employees. Prior positions with Lehman Bothers included, Associate Director of Credit Research, responsible for managing, training and developing new analysts and associates in the Fixed Income Credit Research Department, and as a High Yield Bond Analyst. As an analyst, Ms. Cunningham was a perennial Institutional Investor magazine all-star analyst in the high yield health care category. Her research career has spanned more than 20 years, including both equity and fixed income research for firms such as Kidder, Peabody & Co., and Paine Webber.

“Extendicare REIT is delighted to welcome Ms. Cunningham to its Board of Trustees,” said Mel Rhinelander, Chairman of Extendicare REIT. “Ms. Cunningham will be a valuable board member providing input and guidance as we develop strategies to position Extendicare REIT for continued success. Along with the additions earlier this year of Governor Howard Dean and Ben Hutzel, we feel we have taken important steps to add depth to our Board of Trustees.”

Ms. Cunningham received her A.B. in Applied Mathematics from Harvard University in 1980, and went on to receive an M.S. in Management with a concentration in Finance and Economics from the Sloan School of Management, Massachusetts Institute of Technology, in 1982. As well, she is a Chartered Financial Analyst.

About Us

Extendicare REIT is a leading North American provider of long-term and short-term senior care services through its network of owned and operated health care centers. We employ 37,800 qualified and experienced individuals dedicated to helping people live better through a commitment to quality service that includes post-acute care, rehabilitative therapies and home health care services. Our 263 senior care centers in North America have capacity for approximately 29,200 residents. Extendicare REIT is a specified investment flow-through trust (SIFT) that has been subject to the SIFT tax since January 1, 2007.

Forward-looking Statements

Information provided by Extendicare REIT from time to time, including this release, contains or may contain forward-looking statements concerning anticipated financial events, results, circumstances, economic performance or expectations with respect to the REIT and its subsidiaries, including its business operations, business strategy, and financial condition. Forward-looking statements can be identified because they generally contain the words “expect”, “intend”, “anticipate”, “believe”, “estimate”, “project”, “plan” or “objective” or other similar expressions or the negative thereof. Forward-looking statements reflect management’s beliefs and assumptions and are based on information currently available, and the REIT assumes no obligation to update or revise any forward-looking statement, except as required by applicable securities laws. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the REIT to differ materially from those expressed or implied in the statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on the REIT’s forward-looking statements. Further information can be found in the disclosure documents filed by Extendicare REIT with the securities regulatory authorities, available at www.sedar.com and on the REIT’s website at www.extendicare.com.

SAN FRANCISCO, CA–(Marketwire – August 30, 2010) –  Today at VMworld 2010, QuorumLabs (www.QuorumLabs.com) announced a new release of the onQ Business Continuity Appliance that doubles previous performance and capacity. onQ 2.2 provides one-click instant recovery for up to 25 physical and virtual servers per appliance, and can scale to any number of servers using multiple appliances.

Unlike traditional multi-product enterprise solutions, onQ is a simple, turnkey appliance that pre-integrates a number of sophisticated technologies — such as replication, deduplication, snapshots & continual virtualization — into a single box. onQ automatically maintains and manages up-to-date virtual machine clones on a bare metal hypervisor to give companies high performance instant recovery in the event of a failure without requiring any additional hardware or software. onQ goes beyond off-site and on-line backup and makes complete business continuity easy and affordable — without the complexity, cost, or lengthy deployment projects required of traditional enterprise solutions.

“To provide an equivalent solution to what QuorumLabs has packaged into a single appliance requires a high level of engineering and an extended migration and integration project,” said Bob Boyer, chief marketing officer, Transcend United. “For small and mid-sized companies who need business continuity, this has been a barrier to deploying virtualization-based solutions since they don’t have the in-house expertise or the time. It’s a lot to tackle. That’s where onQ fits in: an easy to implement, easy to maintain and easy to test appliance.”

Price and Availability

QuorumLabs’ partners offer onQ in a variety of ways to meet customer needs, including via managed services, or dual-appliance configurations with up to 13 terabytes internal storage (expandable with external storage) starting at under $15,000 for a pair of replicating appliances. Visit www.QuorumLabs.com to find your local reseller.

About QuorumLabs

QuorumLabs™ develops technologies and products that make enterprise-class technologies such as virtualization easy and affordable for small and medium-sized businesses. QuorumLabs introduced the industry’s first turnkey business continuity solution that ensures One-Click Recovery™. Located in Fremont, California, QuorumLabs was spun out of Themis Computer in 2008. More information about QuorumLabs can be found at www.QuorumLabs.com.

QuorumLabs, onQ, One-Click Recovery, and the QuorumLabs logo are trademarks of QuorumLabs, Inc. in the United States and other countries.

MUNDELEIN, IL–(Marketwire – August 27, 2010) –  Medline Industries, Inc., the nation’s largest privately held manufacturer and distributor of healthcare supplies, today introduced a new CMS Survey Readiness Program for ambulatory surgery centers (ASCs). The program helps ASCs in interpreting new Centers for Medicare and Medicaid Services (CMS) regulatory requirements, preparing for the CMS survey and improving patient safety. CMS recently mandated the new survey process to promote better infection control practices within the estimated 5,300 freestanding ambulatory surgery centers nationwide that account for 53.3 million same-day surgical and non-surgical procedures.

“With more invasive diagnostic and surgical procedures being performed in outpatient settings, CMS has turned its attention to the surgery center market,” said Dirk Benson, Medline’s Vice President of Sales, Ambulatory Surgery Division. “This fast-paced, high-volume environment provides unique challenges and opportunities for infection control and prevention. Medline’s CMS Survey Readiness Program combines educational opportunities, readiness tools and useful resources to help ASCs maintain compliance and retain financial reimbursement for the services they provide.”

Medline’s CMS Readiness Program consists of a series of modules, each designed to address a specific CMS regulation within the survey. The modules are written materials that accompany a series of webinars that ASC staff can attend to prepare for the surveys. Module one, Infection Prevention, is currently available through Medline University (www.medlineuniversity.com), Medline’s free online educational resource. Upcoming modules include: Environmental Compliance of Ambulatory Surgery; Crafting a Quality Assessment Improvement Program; Rules and Regulations for Governing Boards; and Understanding Patient Rights, Admission and Discharge Needs. 

The first webinar, Keys to Successful Ambulatory Surgery Center Surveys, is currently available on Medline University and free to all surgery centers. Participants will learn how to use the program and how the modules will prepare the facility for the survey. At the conclusion of the program, ASCs will have the tools and resources to improve patient safety; pass a CMS survey; potentially prevent interruption in patient care and lost revenue; and reduce staff anxiety and work load by providing a “turn key” program. 

For more information on Medline’s CMS Survey Readiness Program for Ambulatory Surgery Centers visit www.medline.com.

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

NEW YORK, NY–(Marketwire – August 27, 2010) –  The economy of Mexico is challenged by a recession, oil prices, and a falling exchange rate. Yet according to a new report from healthcare market research publisher Kalorama Information, Mexico is still attracting clinical diagnostic companies and showing modest growth. Mexico’s IVD market grew 75% between 2004 and 2009, according to the report “McEvoy and Farmer’s Complete Guide to IVD Distribution in Mexico,” which is a joint publication of Kalorama and emerging IVD market research firm McEvoy and Farmer.

Mexico followed the United States into recession, which has hurt the private side of the in vitro diagnostic market, according to the report. Most diagnostic tests in Mexico are publicly-funded, but the report notes there may be a strain on finances next year due to the fall in the price of oil and an impending budget deficit. The exchange rate has changed from 10.9 pesos per dollar in 2007 to the current level of nearly 13; a sixteen-percent decline over the past two years. 

“The fall of the peso hurts because most IVD products are not manufactured in Mexico,” said Bruce Carlson, Publisher of Kalorama Information. “Still, the analysts see a good number of top-level manufacturers here, and they are betting that when the US comes out of recession, Mexico will follow.”

In the report, Kalorama Information and McEvoy and Farmer detail 18 manufacturers and 30 distributors that are currently competing in Mexico’s IVD market, including Abbott, BD and Bio-Rad.

“McEvoy and Farmer’s Complete Guide to IVD Distribution in Mexico” provides more information, including healthcare statistics, market size numbers for segments of the IVD market and information about distributors and what products they distribute in Mexico. The report can be found at: http://www.kaloramainformation.com/redirect.asp?progid=79516&productid=2768446

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).